Document:

EX-4.2

 Exhibit 4.2 
  

			
	

	 	CLIFFORD CHANCE LLP

 BARCLAYS PLC 
  

 
 BARCLAYS GLOBAL
SHAREPURCHASE PLAN 
  
  

Approved by the Board of the Company on 5 June 2009 

Amended on behalf of the Share Schemes Committee on 26 May 2010 31 January 2017 and 22 May 2018 

Confidential 

 CONTENTS 
  

							
	 	 	 	  	Page	 
			
	 RULE
	 		  			
	 1.
	 	 DEFINITIONS
	  	 	1	 
			
	 2.
	 	 INVITATIONS TO PARTICIPATE IN THE PLAN
	  	 	7	 
			
	 3.
	 	 PARTICIPATION – VESTING PERIOD,RETIREMENT AGE AND GROUP PLANS TREATED AS A SINGLE
PLAN
	  	 	8	 
			
	 4.
	 	 FREE SHARES
	  	 	9	 
			
	 5.
	 	 PARTNERSHIP SHARES
	  	 	9	 
			
	 6.
	 	 MATCHING SHARES
	  	 	12	 
			
	 7.
	 	 DIVIDENDS AND DIVIDEND SHARES
	  	 	12	 
			
	 8.
	 	 LIMITS ON PARTICIPATION
	  	 	14	 
			
	 9.
	 	 REGULATORY AND TAX ISSUES
	  	 	15	 
			
	 10.
	 	 LEAVERS
	  	 	16	 
			
	 11.
	 	 SHARES
	  	 	17	 
			
	 12.
	 	 RIGHTS ISSUES, CAPITALISATION ISSUES AND OTHER VARIATIONS OF CAPITAL
	  	 	17	 
			
	 13.
	 	 RECONSTRUCTION AND TAKEOVER
	  	 	18	 
			
	 14.
	 	 VOTING RIGHTS AND DIRECTIONS
	  	 	19	 
			
	 15.
	 	 SCRIP DIVIDENDS
	  	 	20	 
			
	 16.
	 	 FRACTIONAL ENTITLEMENTS
	  	 	20	 
			
	 17.
	 	 CIRCULARS AND NOTICES
	  	 	20	 
			
	 18.
	 	 DISPOSALS AND PAYMENTS
	  	 	21	 
			
	 19.
	 	 AMENDMENT OF THE PLAN
	  	 	21	 
			
	 20.
	 	 DISPUTES
	  	 	21	 
			
	 21.
	 	 NOTICES
	  	 	21	 
			
	 22.
	 	 TERMS OF EMPLOYMENT
	  	 	22	 
			
	 23.
	 	 THIRD PARTIES
	  	 	22	 
			
	 24.
	 	 BENEFITS NOT PENSIONABLE
	  	 	23	 
			
	 25.
	 	 DATA PROTECTION
	  	 	23	 
			
	 26.
	 	 GOVERNING LAW
	  	 	23	 

  

							
	 SCHEDULE 1
	 	 - ITALIAN SUB-PLAN
	  	 	24	 
			
	 SCHEDULE 2
	 	 – US SUB-PLAN
	  	 	25	 

 Confidential 

			
	

	 	CLIFFORD CHANCE LLP

  

	1.	 DEFINITIONS 

  

	1.1	 In this Plan the following words and expressions have the meanings set opposite them: 

“Acquisition Date” means: 
  

	 	(a)	 in relation to Partnership Shares, the date selected by the Nominee in its absolute discretion being a date
within 30 days (or such other period as may be selected by the Board) after the last date on which the Partnership Share Money in relation to the Partnership Shares was contributed by the Participant; and 

 

	 	(b)	 in relation to Dividend Shares, the date selected by the Nominee in its absolute discretion being a date within
30 days (or such other period as may be selected by the Board) after the date on which the cash dividend is received by the Nominee in respect of Partnership Shares. 

“ADS” means an American Depositary Share being an authorised depositary security representing for the time being 4 Shares in
the Company and being evidenced by an authorised depositary receipt issued by the ADS Issuer and quoted on the New York Stock Exchange; 

“ADS Issuer” means JP Morgan Chase Bank, N.A. or such other bank as the Company may from time to time appoint to issue
authorised depositary receipts; 
 “Any Other Plan” means any employees’ share scheme other than the Plan adopted by
the Company in general meeting which provides for the acquisition of Shares by or on behalf of employees or directors; 
 “Associated
Company” has the meaning set out in Rule 1.2; 
 “Award” means: 

 

	 	(a)	 in relation to Free Shares and/or Matching Shares the grant of a RSU in relation to such Shares (or, if the
Board so determines, ADSs) in accordance with the Plan; and 

  

	 	(b)	 in relation to Partnership Shares and/or Dividend Shares, the acquisition of such Shares (or, if the Board so
determines, ADSs), in accordance with the Plan 

 and the expression “Awarded” and “Award Date “shall
be construed accordingly; 
 “BGI” means Barclays Global Investors UK Holdings Limited; 

“BGI Plan” means the Barclays Global Investors Equity Ownership Plan; 

“BGI Shares” means “A” Ordinary Shares in the capital of BGI; 

“Board” means the board of directors of the Company or a duly authorised committee of the Board; 

  
 Confidential 

-1- 

			
	

	  	CLIFFORD CHANCE LLP

  

“Capital Receipt” means in respect of a Participant’s Plan Shares, any money or money’s worth except to the extent
that: 
  

	 	(a)	 it constitutes income in the hands of the recipient for the purposes of income tax; 

 

	 	(b)	 it consists of the proceeds of disposal of the Plan Shares in respect of which it is received; or

  

	 	(c)	 it consists of New Shares; 

“Company” means Barclays PLC (registered in England and Wales with registered number 48839); 

“Connected Company” means: 
  

	 	(a)	 a company which Controls or is Controlled by the Company or which is Controlled by a company which also
Controls the Company; or 

  

	 	(b)	 a company which is a member of a consortium owning the Company or which is owned in part by the Company as a
member of a consortium; 

 “Control”, together with related expressions, means, in relation to a company
(“company A”), the power of a person to secure: 
  

	 	(a)	 by means of the holding of shares or the possession of voting power in relation to that or any other company;
or 

  

	 	(b)	 as a result of any powers conferred by the articles of association or other document regulating that or any
other company, 

 that the affairs of company A are conducted in accordance with the person’s wishes; 

“Dealing Day” means: 
  

	 	(a)	 where Shares are acquired by the Nominee, a day on which transactions take place on the London Stock Exchange;
and 

  

	 	(b)	 where ADSs are acquired by the Nominee, a day on which transactions take place on the New York Stock Exchange;

 “Dividend Shares” means Shares, including fractions of Shares, which are acquired on behalf of a
Participant by the Nominee using cash dividends received in respect of the Participant’s Plan Shares and reinvested in accordance with Rule 7 for the time being held by the Nominee on his behalf pursuant to the Plan and which are: 

 

	 	(a)	 of the same class and carry the same rights as the Plan Shares in respect of which the cash dividend is paid;
and 

  

	 	(b)	 not subject to forfeiture 

and where the context so admits includes any New Shares held by the Nominee on behalf of the Participant pursuant to the Plan; 

  
 Confidential 

-2- 

			
	

	  	CLIFFORD CHANCE LLP

  

“Eligible Employee” means any person who: 
  

	 	(a)	 is an employee of a Participating Company in a Participating Jurisdiction on the Qualifying Date;

  

	 	(b)	 is not eligible at the same time to participate in an award of shares under a UK
tax-approved share incentive plan established by any member of the Group; and 

  

	 	(c)	 has on the Qualifying Date such Qualifying Period (if any) of continuous employment with the Company or any
Qualifying Company as the Board may determine; 

 “Free Shares” means Shares, including fractions
of Shares, in respect of which a RSU has been granted to a Participant; 
 “Group” means the Company and its Subsidiaries
and “member of the Group” shall be construed accordingly; 
 “ICTA” means the Income and Corporation Taxes Act
1988; 
 “Initial Market Value” means: 
  

	 	(a)	 if and for so long as the Shares are admitted to the Official List of the UK Listing Authority, in relation to
Partnership Shares and Dividend Shares which are: 

  

	 	(i)	 acquired wholly or partly by the Nominee by subscription, the average of the middle market quotations of a
Share as derived from the Daily Official List of the UK Listing Authority over the period of five consecutive Dealing Days ending immediately before the Acquisition Date as determined by the Nominee; or 

 

	 	(ii)	 acquired by the Nominee by purchase, the average purchase price per Share paid by the Nominee (excluding the
costs of purchase and stamp duties) to purchase Shares on the Acquisition Date; or 

  

	 	(iii)	 acquired by the Nominee by subscription and/or by purchase, such value per Share calculated on such other basis
as may be determined by the Nominee and agreed with the Company; 

  

	 	(b)	 in the case of Partnership Shares and/or Dividend Shares Awarded as ADSs quoted on the New York Stock Exchange,
the provisions of (a) shall apply but with the relevant price(s) being the closing price(s) of ADSs on the New York Stock Exchange; 

  

	 	(c)	 if the Shares are not admitted to the Official List of the UK Listing Authority (or, as the case may be, ADSs
are not traded on the New York Stock Exchange), in 

  
 Confidential 

-3- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	
relation to Partnership Shares and Dividend Shares, on any day the market value of a Share (or an ADS) determined in accordance with the provisions of Part VIII of the Taxation of Chargeable
Gains Act 1992; 

 “ITEPA” means the Income Tax (Earnings and Pensions) Act 2003; 

“London Stock Exchange” means the London Stock Exchange plc; 

“Matching Shares” means Shares, including fractions of Shares, in respect of which a RSU has been granted to a Participant in
connection with an Award of Partnership Shares; 
 “New York Stock Exchange” means The New York Stock Exchange, Inc.; 

“New Shares” means: 
  

	 	(a)	 shares or other securities acquired in respect of Plan Shares where such shares or securities are equated with
the Plan Shares for the purposes of UK capital gains tax; or 

  

	 	(b)	 shares or other securities that would fall within paragraph (a) above but for the fact that they consist
of or include a qualifying corporate bond for UK capital gains tax purposes; 

 “Nominee” means, as
the context requires, the person holding Shares for the purposes of the Plan or the person acting as administrator of the Plan, in each case being such person or persons as may be selected by the Board from time to time; 

“Participant” means any Eligible Employee to whom the Nominee has Awarded Shares; 

“Participating Company” means the Company and any Subsidiary which participates in the Plan and which is bound by the
provisions of the Plan; 
 “Participating Jurisdiction” means a jurisdiction in which the Board has determined that
invitations to participate in the Plan will be issued under Rule 2; 
 “Partnership Shares” means Shares, including
fractions of Shares, which are acquired on behalf of a Participant by the Nominee under Rule 5 and are registered in the name of the Nominee (or any other person nominated by the Board) to be held by the Nominee on behalf of the Participant pursuant
to the Plan and where the context so admits includes any New Shares held by the Nominee on his behalf pursuant to the Plan; 

“Partnership Share Agreement” means an agreement in such form as determined by the Board from time to time made between the
Company, the Nominee and an Eligible Employee under which: 
  

	 	(a)	 the Eligible Employee authorises the Company to deduct (or procure that his employing Participating Company
deducts) part of his Salary for the acquisition of Partnership Shares; and 

  
 Confidential 

-4- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	(b)	 the Company agrees to give effect to the agreement by making (or procuring that the relevant Participating
Company makes) deductions from such employee’s Salary of such amount and at such intervals as may be agreed from time to time (subject to the limits in Rule 5.2) and undertakes to arrange for the acquisition of Partnership Shares by the Nominee
on behalf of the Eligible Employee in accordance with the Plan using the amounts so deducted; or 

  

	 	(c)	 the Eligible Employee otherwise agrees to make payments for the acquisition of Partnership Shares (subject to
the limits in Rule 5.2) on terms approved by the Company 

 (all such deductions or payments being referred to as
“contributions” (or related expressions) in the Rules); 
 “Partnership Share Money” means amounts contributed by
an Eligible Employee under the terms of a Partnership Share Agreement; 
 “Plan” means the Barclays Global Sharepurchase
Plan; 
 “Plan Shares” means Free Shares, Matching Shares, Partnership Shares and Dividend Shares (but, in the case of Free
Shares and Matching Shares, only on or after the date of Vesting of such Shares); 
 “Qualifying Company” means a company
that: 
  

	 	(a)	 is a Participating Company at the end of the Qualifying Period; or 

 

	 	(b)	 when the individual was employed by it was a Participating Company or an Associated Company of the
Participating Company or of any other Qualifying Company; 

 “Qualifying Date” means the date on which
eligibility to participate in the Plan is determined being, in the case of Partnership Shares or Matching Shares, the date that Partnership Share Money is contributed in respect of the Partnership Shares, and, in the case of Free Shares, the Award
Date or subject to the definition of “Qualifying Period” such other date determined by the Nominee; 
 “Qualifying
Period” means, in the case of Partnership Shares with or without Matching Shares and Free Shares, a period of not more than 18 months ending with (a) the contribution of the Partnership Share Money relating to the Partnership Shares in
the case of Partnership Shares and Matching Shares and (b) the Award Date in the case of Free Shares, but in each case so that in respect of an Award the same Qualifying Period applies to all Eligible Employees; 

“Reconstruction or Takeover” means any of the following transactions which affect Plan Shares: 

 

	 	(a)	 an offer for any of the Participant’s Plan Shares if the acceptance or agreement of the offer will result
in New Shares being acquired in respect of such Plan Shares; 

  
 Confidential 

-5- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	(b)	 a transaction affecting the Participant’s Plan Shares, or such of them as are of a particular class, if
the transaction would be entered into as a result of a compromise, arrangement or scheme applicable to or affecting: 

  

	 	(i)	 all the ordinary shares in the capital of the Company or, as the case may be, all the shares of the class in
question; or 

  

	 	(ii)	 all the shares, or all the shares of the class in question, which are held by a class of shareholders
identified otherwise than by reference to their employment or their participation in the Plan; or 

  

	 	(c)	 an offer for the Participant’s Plan Shares of: 

 

	 	(i)	 cash, with or without assets, or 

 

	 	(ii)	 a qualifying corporate bond for UK capital gains tax purposes (whether alone or with other assets or cash or
both) 

 if the offer forms part of a general offer that is made: 

 

	 	(iii)	 to holders of shares of the same class as the Participant’s Plan Shares or to holders of Shares; and

  

	 	(iv)	 in the first instance on a condition such that if it is satisfied the person making the offer will have control
of the Company within the meaning of section 416 of ICTA; 

 “Relevant Amount” means £3,600 or such
other amount as may be prescribed from time to time in the UK SIP; 
 “RSU” means a restricted share unit granted by
the Company, being a conditional right to acquire Free Shares or Matching Shares; 
 “Rules” means the rules of the Plan as
amended from time to time; 
 “Salary” means (a) the pre-tax cash earnings of
the Participant’s employment for the purposes of the 10 per cent limit specified in Rule 5.2, or (b) in all other cases, the post-tax cash earnings of the Participant’s employment, with, in
each case, the reference to employment being to the employment by reference to which the Participant is eligible to participate in the Plan; 

“Share” means an ordinary share in the capital of the Company or, where the context permits, New Shares; 

“Subsidiary” means any company which is for the time being under the Control of the Company and which is a subsidiary within
the meaning given by section 1159 of the Companies Act 2006; 
 “Tax Liability” means any amount of tax or social security
contributions for which any Participant would or may be liable and for which any member of the Group would or may be obliged to (or would or may suffer a disadvantage if it were not to) account to any relevant authority;

  
 Confidential 

-6- 

			
	

	  	CLIFFORD CHANCE LLP

  

“UK Listing Authority” means the UK Listing Authority within the meaning given to that expression in the Listing Rules made by the Financial Services Authority pursuant to its
appointment as the relevant competent authority under the Official Listing of Securities (Change of Competent Authority) Regulations 2000; 

“UK SIP” means the Barclays Group Share Incentive Plan dated 10 January 2002 and approved by HM Revenue &
Customs on 14 January 2002; 
 “Vesting”, together with related expressions, means in relation to Free Shares and/or
Matching Shares a Participant becoming entitled to have a whole number of such Shares transferred to him (or his nominee) subject to the Rules, together with a cash sum in respect of any such fractional Shares; 

“Vesting Period” in relation to Free Shares and/or Matching Shares means the period specified by the Board after which a
Participant shall be entitled to have a whole number of such Shares transferred to him (or his nominee) subject to the Rules, together with a cash sum in respect of any such fractional Shares. 

 

	1.2	 One company is an Associated Company of another company at a given time if: 

 

	 	(a)	 one has control of the other; or 

 

	 	(b)	 both are under the control of the same person or persons (control for these purposes being defined by reference
to Sections 416(2) to 416(6) of ICTA). 

  

	1.3	 Any reference to Shares shall, where the context so permits or requires, be deemed to be a reference to ADSs.

  

	1.4	 For the purposes of a Participant’s compliance with the individual participation limits referred to in the
proviso to Rule 4.2 (limit on the maximum aggregate Initial Market Value of all Free Shares which may be Awarded) and Rule 5.2 (limits on the maximum amount of Partnership Share Money), the Board shall from time to time set an exchange rate between
the relevant local currency and sterling and shall stipulate the period during which such exchange rate shall apply. 

  

	1.5	 References to any statutory provisions are to those provisions as amended, extended or re-enacted from time to time and shall include any regulations made thereunder and, unless the context otherwise requires, words in the singular include the plural (and vice versa) and words importing any gender
include all genders. 

  

	2.	 INVITATIONS TO PARTICIPATE IN THE PLAN 

 

	2.1	 Subject to Rule 9, the Board may at any time and from time to time in its absolute discretion resolve that the
Plan shall be operated or shall cease to be operated in respect of any or all of Free Shares, Partnership Shares, Matching Shares or Dividend Shares (or, in each such case, ADSs in the case of US Participants) in accordance with the provisions of
the Plan. 

  
 Confidential 

-7- 

			
	

	  	CLIFFORD CHANCE LLP

  

	2.2	 If the Board exercises its discretion in Rule 2.1 and resolves to operate the Plan then, unless otherwise
determined by the Board: 

  

	 	(a)	 the Board shall invite every Eligible Employee to participate in the Plan on the same terms in respect of any
Award and every Eligible Employee who participates in the Plan shall do so on the same terms; and 

  

	 	(b)	 the Board shall issue an invitation in accordance with the Rules (in such form as the Board shall determine
from time to time) to: 

  

	 	(i)	 each Eligible Employee who is not a Participant; and 

 

	 	(ii)	 if applicable, to each Eligible Employee who has since the Plan was operated, revoked a notice previously
served by him under Rule 2.3; and 

  

	 	(iii)	 all employees who at the next Qualifying Date are expected to be Eligible Employees, 

and an Eligible Employee may (1) accept the opportunity to acquire Partnership Shares and/or Matching Shares by submitting a completed
Partnership Share Agreement by the date specified in the letter of invitation or (2) accept an Award of Free Shares in such manner (if any) as the Board may prescribe. If the completed Partnership Share Agreement (or, if applicable, a form of
acceptance in relation to Free Shares) is not submitted by the date specified in the invitation, the Eligible Employee shall be deemed to have declined to participate in the Plan at that time. 

 

	2.3	 An individual may by notice given to the Company on terms acceptable to the Company before Partnership Share
Money is contributed direct that Partnership Shares shall not be Awarded to him or acquired on his behalf on the next Acquisition Date or on any subsequent Acquisition Date. A notice given by an individual under this Rule may be revoked by that
individual giving the Company a notice of revocation. 

  

	3.	 PARTICIPATION – VESTING PERIOD, RETIREMENT AGE AND GROUP PLANS TREATED AS A SINGLE PLAN

  

	3.1	 The Board shall specify a Vesting Period in respect of each Award of Free Shares or Matching Shares. Such
Vesting Period shall be specified in the Partnership Share Agreement (in the case of Matching Shares) or in the Award grant documentation (in the case of Free Shares) PROVIDED THAT: 

 

	 	(a)	 the Board may specify different Vesting Periods from time to time; 

 

	 	(b)	 unless otherwise determined by the Board, the Vesting Period must be the same for all Free Shares or Matching
Shares Awarded at the same time; and 

  

	 	(c)	 unless otherwise specified by the Board, the Vesting Period shall be three years. 

  
 Confidential 

-8- 

			
	

	  	CLIFFORD CHANCE LLP

  

	3.2	 If an Eligible Employee participates in an Award under the Plan in a calendar year in which he has already
participated in an award of shares under the UK SIP or other similar share incentive plans established by the Company or a Connected Company, then the limits specified in the proviso to Rule 4.2 and Rule 5.2 apply as if the Plan and the other plan
or plans were a single plan. 

  

	4.	 FREE SHARES 

  

	4.1	 If the Board in its absolute discretion resolves that the Plan shall be operated in respect of Free Shares the
Board shall determine the maximum value of Awards to be granted over Free Shares on every occasion on which the Board decides to operate the Plan in respect of Free Shares and shall notify the Participating Companies accordingly.

  

	4.2	 Subject to any reduction or limit imposed by Rule 8, the number of Free Shares to be Awarded to each Eligible
Employee on any Award Date shall be determined by the Board in accordance with any one or more of the following formulae: 

  

	 	(a)	 each Eligible Employee shall receive a fixed number of Free Shares or a number of Shares with an Initial Market
Value equal to a fixed sum; 

  

	 	(b)	 each Eligible Employee shall receive Free Shares having an Initial Market Value equal to such percentage of his
remuneration as the Board shall determine; 

  

	 	(c)	 each Eligible Employee shall receive a number of Free Shares depending on his length of service with a
Qualifying Company; 

  

	 	(d)	 each Eligible Employee shall receive a number of Free Shares depending on the number of hours worked; or

  

	 	(e)	 if the Board decides that performance allowances are to be used each Eligible Employee shall receive a number
of Free Shares which is conditional on performance targets and measures notified as soon as practicable to each Eligible Employee having been met 

PROVIDED THAT (a) the aggregate Initial Market Value of all Free Shares which may be Awarded to any Participant in any calendar year shall
not exceed the Relevant Amount; and (b) where the number of Free Shares depends on more than one of the formulae in sub-paragraphs (b), (c) and (d) above, each factor must give rise to a separate
entitlement and the total entitlement is the sum of those separate entitlements. 
  

	4.3	 The Participating Companies shall provide such sums as may be requested by the Company to purchase Shares to be
Awarded to Eligible Employees as Free Shares pursuant to this Rule. 

  

	5.	 PARTNERSHIP SHARES 

 

	5.1	 The Board may from time to time in its absolute discretion invite Eligible Employees to acquire Partnership
Shares. To participate in an Award of Partnership Shares, each Eligible Employee must first enter into a Partnership Share Agreement with the Company and the Nominee in respect of contributions to be made by the Eligible Employee.

  
 Confidential 

-9- 

			
	

	  	CLIFFORD CHANCE LLP

  

	5.2	 The amount of Partnership Share Money which may be contributed by an Eligible Employee must not exceed the
lowest of: 

  

	 	(a)	 £1,800 in any calendar year (or the equivalent in local currency which may, if the Board so permits, be
rounded up to such local currency amount as the Board decides provided that such amount shall not be materially greater than £1,800); 

  

	 	(b)	 10% of the Eligible Employee’s Salary for the calendar year; and 

 

	 	(c)	 such lower limit as may be specified by the Board from time to time, 

and each contribution shall not be less than £10 or the equivalent in local currency which may, if the Board so permits, be rounded up to
such local currency amount as the Board decides provided that such amount shall not be materially greater than £10 (or such other minimum amount specified by the Board from time to time). 

 

	5.3	 Partnership Share Money must be paid to the Nominee, once contributed to the Company or any Participating
Company, as soon as practicable. 

  

	5.4	 Partnership Share Money shall be held by the Nominee in a
non-interest-bearing account until it is applied in acquiring Partnership Shares on behalf of the relevant Eligible Employee. 

 

	5.5	 Partnership Share Money shall be applied by the Nominee in the acquisition of Partnership Shares on behalf of
the relevant Eligible Employee on the Acquisition Date. 

  

	5.6	 The Company may specify a maximum number of Shares over which Awards of Partnership Shares may be made on any
one occasion. The Partnership Share Agreement shall require the Company to notify relevant Eligible Employees of any such maximum before the contribution of Partnership Share Money in respect of that Award. 

 

	5.7	 If the Company receives applications for Partnership Shares in excess of the maximum determined by the Board in
accordance with Rule 5.6 the Board shall adjust individual applications downwards either: 

  

	 	(a)	 on a pro-rata basis; or 

 

	 	(b)	 on such other basis as the Board may determine 

PROVIDED THAT 
  

	 	(i)	 if possible, each applicant who so wishes should be able to participate at least to the extent represented by
the minimum monthly amount pursuant to Rule 5.2; 

  

	 	(ii)	 if there are insufficient Shares available to allow full participation based on the minimum monthly amount,
then participation based on such minimum monthly amount shall be afforded to those applicants who are selected at random in a ballot conducted by the Board. 

  
 Confidential 

-10- 

			
	

	  	CLIFFORD CHANCE LLP

  

	5.8	 The number of Partnership Shares Awarded to each Eligible Employee shall be determined in accordance with their
Initial Market Value. As soon as practicable after any Partnership Shares have been acquired by the Nominee on behalf of a Participant, the Nominee shall notify the Participant (in such form as determined by the Nominee from time to time) of the
acquisition specifying the number and description of those Shares, the amount of Partnership Share Money applied by the Nominee in the acquisition and their Initial Market Value. 

 

	5.9	 Subject to any Tax Liability, Partnership Shares may be withdrawn from the Plan at any time but on the basis
that any Award of Matching Shares granted to a Participant in connection with the withdrawn Partnership Shares shall thereupon automatically lapse to the extent that such Award has not Vested at that time. 

 

	5.10	 A Participant may at any time give notice to the Company to stop contributions pursuant to a Partnership Share
Agreement. A Participant may subsequently give notice to the Company to restart contributions by giving notice to the Company. Where a notice is received stopping contributions, contributions will be stopped no later than 30 days following the date
of receipt unless a later date is specified in the notice. Where a notice to re-start contributions is received, contributions will be restarted no later than the first contribution due following 30 days from
the date of receipt of the notice unless a later date is specified in the notice. 

  

	5.11	 The Company may at any time give notice to the Participant to stop contributions pursuant to a Partnership
Share Agreement to acquire Partnership Shares. The Company may subsequently give notice to the Participant to restart contributions. Where a notice is given stopping contributions, contributions will be stopped no later than 30 days following the
date the notice is given unless a later date is specified in the notice. Where a notice to restart contributions is given, contributions will be restarted no later than the first contribution due following 30 days from the date the notice is given
unless a later date is specified in the notice. 

  

	5.12	 For so long as any Partnership Shares are admitted to the Official List of the UK Listing Authority and held by
the Nominee, a Participant may only sell any such Shares on the London Stock Exchange by arrangements made with the Nominee. The same principle shall apply to ADSs traded on the New York Stock Exchange. 

 

	5.13	 A Participant may withdraw from a Partnership Share Agreement at any time by notice to the Company. Unless a
later date is specified, any such notice shall take effect 30 days from the date of receipt. 

  

	5.14	 If a Participant withdraws from a Partnership Share Agreement after the date on which Partnership Share Money
is contributed, the Nominee shall apply those monies towards the acquisition of Partnership Shares on the next Acquisition Date and shall return any Partnership Share Money that is less than the market value of a Share held by the Nominee to the
relevant Eligible Employee as soon as practicable. 

  
 Confidential 

-11- 

			
	

	  	CLIFFORD CHANCE LLP

  

	5.15	 If a Participant withdraws from a Partnership Share Agreement before the date on which Partnership Share Money
is contributed, the Nominee shall not apply those monies towards the acquisition of Partnership Shares on the next Acquisition Date and shall return any Partnership Share Money held by the Nominee to the relevant Eligible Employee as soon as
practicable. 

  

	6.	 MATCHING SHARES 

 

	6.1	 If the Board from time to time in its absolute discretion decides to offer Matching Shares in conjunction with
an invitation to acquire Partnership Shares in accordance with Rule 5, the following provisions shall apply. 

  

	6.2	 The Participating Companies shall provide such sums as may be requested by the Company to purchase Shares to be
Awarded to Eligible Employees as Matching Shares pursuant to this Rule. 

  

	6.3	 The number of Matching Shares to be awarded by way of the grant of RSUs to each Eligible Employee on the
occasion on which Partnership Shares are acquired on behalf of each such Eligible Employee shall be calculated by applying the ratio specified in the Partnership Share Agreement which shall, unless the Board determines otherwise, be the same for all
Eligible Employees for that Award to the number of Partnership Shares to be acquired on that occasion PROVIDED THAT the ratio shall not exceed two Matching Shares for each Partnership Share. 

 

	6.4	 Unless the Board determines otherwise, Matching Shares shall be Awarded at the same time (so far as possible)
as the Partnership Shares to which they relate are Awarded and on the same basis to all Eligible Employees who participate in the Award. 

  

	6.5	 As soon as practicable after any Matching Shares have been awarded to a Participant, the Nominee shall give
details thereof to that Participant. 

  

	7.	 DIVIDENDS AND DIVIDEND SHARES 

 

	7.1	 The Board may from time to time, in its absolute discretion, direct that: 

 

	 	(a)	 all cash dividends received in respect of Partnership Shares and/or Dividend Shares and/or Free Shares and/or
Matching Shares (as the Board decides) must be reinvested in acquiring more Shares; or 

  

	 	(b)	 cash dividends received in respect of Partnership Shares and/or Dividend Shares and/or Free Shares and/or
Matching Shares (as the Board decides) of those Participants who so elect must be reinvested by the Nominee in acquiring more Shares on behalf of those Participants. 

 

	7.2	 If Rule 7.1(a) applies or a Participant makes an election under Rule 7.1(b), any cash dividend received by the
Nominee in respect of the relevant Plan Shares held on behalf 

  
 Confidential 

-12- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	
of a Participant shall be applied by the Nominee in acquiring more Shares on his behalf on the Acquisition Date and the number of Dividend Shares acquired on his behalf shall be determined by the
Nominee in accordance with their Initial Market Value. 

  

	7.3	 As soon as practicable after any Dividend Shares have been acquired on behalf of a Participant, the Nominee
shall notify the Participant (in such form as the Nominee shall determine from time to time) of the acquisition specifying the number and description of those Shares, their Initial Market Value and any amount of uninvested cash dividends held by the
Nominee on behalf of the Participant. 

  

	7.4	 The Nominee shall reinvest dividends in a way that is fair and equal between Participants.

  

	7.5	 If the Board does not make a direction under Rule 7.1(a) or a Participant does not make an election under Rule
7.1(b), the Nominee shall pay the cash dividend or any balance thereof to the Participant as soon as practicable. 

  

	7.6	 The Board may from time to time in its absolute discretion by notice given to all Eligible Employees revoke a
direction given under Rule 7.1 in which case any election made by a Participant under Rule 7.1(b) would immediately cease to have effect. 

  

	7.7	 A Participant may at any time by notice to the Company request that his Dividend Shares be removed from the
Plan. Unless a later date is specified, any such notice shall take effect 30 days from the date of receipt. 

  

	7.8	 For so long as any Dividend Shares are admitted to the Official List of the UK Listing Authority and held by
the Nominee, a Participant may only sell any such Shares on the London Stock Exchange by arrangements made with the Nominee. The same principle shall apply to ADSs traded on the New York Stock Exchange. 

 

	7.9	 Subject to Rule 7.10, any Award of Free Shares and/or Matching Shares may be granted on terms whereby the
number of Shares comprised in the Award shall increase by deeming dividends (excluding special dividends, unless the Board decides otherwise) paid on the Shares from the Award Date to Vesting to have been reinvested in additional Shares on such
terms (as to the inclusion or exclusion of any dividend tax credit, the price at which any additional Shares shall be deemed to have been purchased or otherwise) as the Board shall decide. 

 

	7.10	 The Board may determine that, in respect of any Award of Free Shares and/or Matching Shares, a Participant may
either: 

  

	 	(a)	 be entitled to receive a benefit on the Vesting of such an Award determined by reference to the value of all or
any of the dividends (excluding special dividends, unless the Board determines otherwise) paid on the Shares from the Award Date to Vesting and on the basis that such benefit may (i) be provided in cash or Shares and (ii) include or
exclude any dividend tax credits (in each case, at the Board’s discretion); or 

  

	 	(b)	 not be entitled to receive any benefit related to such dividends. 

  
 Confidential 

-13- 

			
	

	  	CLIFFORD CHANCE LLP

  

	8.	 LIMITS ON PARTICIPATION 

 

	8.1	 The number of Free Shares and Matching Shares to be Awarded to an Eligible Employee shall be reduced in
accordance with the provisions of Rule 8.3 if the total number of unissued Free and Matching Shares Awarded under the Plan: 

  

	 	(a)	 in that calendar year would otherwise exceed one per cent. of the Company’s ordinary share capital then in
issue; and/or 

  

	 	(b)	 during the previous ten years when aggregated with any other Shares issued or capable of being issued under Any
Other Plan during such period would otherwise exceed ten per cent of the Company’s issued ordinary share capital then in issue. 

PROVIDED THAT for the purpose of applying the limit set out in Rule 8.1(b) the number of Free and Matching Shares which may be Awarded under
the Plan shall be reduced by the number of notional Shares determined by the Board in the manner set out in Rule 8.2. 
  

	8.2	 For the purposes of the proviso to Rule 8.1: 

 

	 	(a)	 the Board shall compute the number of BGI Shares which have been acquired on exercise of options granted under
the BGI Plan in the relevant period or in respect of which options under the BGI Plan are currently outstanding (less any BGI Shares issued on the exercise of options granted under the BGI Plan but subsequently purchased by Barclays Bank PLC or any
other member of the Group); and 

  

	 	(b)	 the Board shall subject to such adjustment or variation as the Board shall in its absolute discretion consider
appropriate convert such BGI Shares into a notional number of Shares by the application in relation to each such acquisition of or grant of options over, BGI Shares of the formula: 

 

					
	 A x B
	  	=	  	D where:
	C	  		  	

  

	 	A	 is the number of BGI Shares acquired by or under option to each relevant employee; 

 

	 	B	 is the price per BGI Share at which such employee acquired or may acquire such number of BGI Shares;

  

	 	C	 is if and for so long as the Shares are admitted to the Official List of the UK Listing Authority the greater
of the market value of a Share: 

  

	 	(i)	 on the date of grant such options; and 

  
 Confidential 

-14- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	(ii)	 on the date of any determination by the Board for the purposes of this Rule 8.2; 

calculated by the Board by reference to the middle-market quotations of a Share as derived from the Daily Official List of the UK Listing
Authority or if the Shares are not so admitted on such other basis as the Board shall in its absolute discretion determine; 
  

	 	D	 is the number of notional Shares represented by the BGI Shares acquired in the relevant period or in respect of
which options are currently outstanding under the BGI Plan for the purposes of the proviso to Rule 8.1. 

  

	8.3	 If it is not possible to Award to all Eligible Employees Free Shares and/or Matching Shares to meet the
allocation basis described in Rule 4.2 because of any provision of this Rule 8, the number of Free Shares and/or Matching Shares to be Awarded to each Eligible Employee shall be scaled down on a pro rata basis or in such other manner as may be
determined by the Board. 

  

	9.	 REGULATORY AND TAX ISSUES 

 

	9.1	 Any event relating to Shares (whether in connection with the acquisition or disposal thereof or the payment or re-investment of dividends thereon or otherwise) shall not occur unless and until the following conditions are satisfied: 

  

	 	(a)	 the event would be lawful in all relevant jurisdictions and in compliance with the Listing Rules, Market Abuse
Regulation, any relevant securities dealing code of the Company, the City Code on Takeovers and Mergers, the listing rules of the New York Stock Exchange and any other relevant UK or overseas regulation or enactment; 

 

	 	(b)	 if a Tax Liability would arise by virtue of such event, the Participant must have entered into arrangements
acceptable to the Board that the relevant member of the Group will receive the amount of such Tax Liability; 

  

	 	(c)	 the Participant has entered into such arrangements as the Board requires (and where permitted in the relevant
jurisdiction) to satisfy the liability of a member of the Group to pay tax and/or social security contributions in respect of the event; 

  

	 	(d)	 in the case of an Award made to a Participant who is subject to taxation in India, to the extent that any
fringe benefit tax liability arises in India for any member of the Group or any Associated Company (the “Liable Company”) in relation to such an Award, the Participant shall be under an obligation to make arrangements satisfactory to the
Company to pay (whether by way of deduction from any amounts payable to the Participant or otherwise) to the Liable Company an amount equal to the fringe benefit tax that is payable by the Liable Company in respect of the Award, as determined by the
Liable Company; and 

  
 Confidential 

-15- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	(e)	 where the Board requires, the Participant has entered into, or agreed to enter into, a valid election under
Part 7 of ITEPA (Employment income: elections to disapply tax charge on restricted securities) or any similar arrangement in any overseas jurisdiction. 

For the purposes of this Rule 9.1, references to a member of the Group include any former member of the Group. 

 

	9.2	 On or as soon as reasonably practicable after the Vesting of a RSU, the Board shall transfer or procure the
transfer of the Shares in question to the Participant (or a nominee for him). 

  

	10.	 LEAVERS 

  

	10.1	 If a Participant ceases to be a director or employee by reason of:- 

 

	 	(a)	 death; 

  

	 	(b)	 retirement with the agreement of the Participant’s employer; 

 

	 	(c)	 injury; 

  

	 	(d)	 disability; 

  

	 	(e)	 redundancy; 

  

	 	(f)	 the Participant’s employing company ceasing to be the Company or an Associated Company of the Company; or

  

	 	(g)	 a transfer of the Participant’s employing business to a person who is neither the Company nor an
Associated Company of the Company 

 the Partnership Shares and/or Dividend Shares (in each case, in whole numbers only)
held by the Nominee for such Participant will be transferred to the Participant (or his/her personal representatives in the case of death) as soon as practicable thereafter, together with a cash sum in respect of the value of any fractional
Partnership Shares and/or Dividend Shares so held. 
  

	10.2	 Upon such an event occurring, all of the Free Shares and/or all the Matching Shares Awarded to such Participant
will immediately Vest and such Vested Free Shares and/or Vested Matching Shares (in each case, in whole numbers only), together with a cash sum in respect of any fractional Free Shares and/or Matching Shares that so Vest will be transferred to the
Participant as soon as practicable thereafter (other than in the event of death, in which case all such Free Shares and/or Matching Shares (in each case, in whole numbers only), together with a cash sum in respect of any fractional Free Shares
and/or Matching Shares will be transferred to the personal representatives of the deceased Participant) as soon as practicable thereafter. 

  
 Confidential 

-16- 

			
	

	  	CLIFFORD CHANCE LLP

  

	10.3	 If a Participant ceases to be a director or employee for any reason other than those specified in Rule 10.1,
then the Partnership Shares and/or Dividend Shares (in each case, in whole numbers only) held by the Nominee for such Participant, together with a cash sum in respect of any fractional Partnership Shares and/or Dividend Shares so held will be
transferred to the Participant as soon as practicable thereafter but any Award of Free Shares or Matching Shares held by him shall, to the extent not Vested, immediately lapse on such cessation. 

 

	10.4	 A Participant shall not be treated for the purpose of this Rule 10 as ceasing to be a director or employee
until such time as he is no longer a director or employee of (a) any member of the Group or (b) any Associated Company. If any Participant ceases to be such a director or employee before the Vesting of his Award in circumstances where he
retains a statutory right to return to work then he shall be treated as not having ceased to be such a director or employee until such time (if at all) as he ceases to have such a right to return to work while not acting as an employee or director.

  

	11.	 SHARES 

  

	11.1	 Shares subscribed for under the Plan shall rank pari passu in all respects with Shares then in issue except
they will not rank for any rights attaching to the Shares by reference to a record date preceding the date of issue. 

  

	11.2	 If and for so long as Shares are admitted to the Official List of the UK Listing Authority the Company (or any
successor company) shall apply to the UK Listing Authority for a listing and to the London Stock Exchange for permission to trade for any Shares issued pursuant to the Plan as soon as practicable after the allotment thereof. 

 

	11.3	 If and for so long as ADSs are traded on the New York Stock Exchange (“NYSE”) the Company (or
any successor company) shall apply to the NYSE for permission to trade for any ADSs issued pursuant to the Plan as soon as practicable after the allotment thereof. 

 

	12.	 RIGHTS ISSUES, CAPITALISATION ISSUES AND OTHER VARIATIONS OF CAPITAL 

 

	12.1	 Whenever any rights to acquire New Shares are granted by a company to the holders of any class of shares of
which some are Plan Shares the Nominee shall notify each Participant of the rights relating to his Plan Shares and he may give notice to the Nominee instructing him to do one or more of the following: 

 

	 	(a)	 subject to the provision by him of any necessary funds, to take up or sell all or any of the rights or allow
them to lapse; and/or 

  

	 	(b)	 to sell rights nil paid to the extent necessary to enable the Nominee to subscribe in full for the balance of
any unsold rights 

 which instructions may be particular or of general application and relate to Plan Shares appropriated
before and after the date of the relevant rights issue. 

  
 Confidential 

-17- 

			
	

	  	CLIFFORD CHANCE LLP

  

	12.2	 The Nominee shall act upon any such notice received by him not less than five Dealing Days before the expiry of
the period allowed for the exercise of any such rights. If any Participant has not prior to five Dealing Days before the expiry of the period allowed for the exercise of any such rights, given notice to the Nominee instructing him to take action
with regard thereto and provided any funds necessary for the purpose, the Nominee shall allow such rights to lapse. The Nominee shall deal with any Capital Receipt received in consequence of the non-exercise
or sale of any rights in accordance with Rule 18.1. 

  

	12.3	 Any New Shares taken up by the Nominee on behalf of any Participant under Rule 12.1(b) shall, subject to Rule
13, form part of the Participant’s Plan Shares and shall be deemed to have been acquired on behalf of the Participant in the same way and at the same time as the Participant’s Plan Shares to which they relate PROVIDED THAT this Rule 12.3
shall not apply in relation to rights arising under a rights issue to subscribe shares in a company unless similar rights are conferred in respect of all ordinary shares in the company. 

 

	12.4	 Nothing in this Rule shall require the Nominee to act in any manner whereby he would be involved in any
liability unless indemnified to his satisfaction by the Participant against such liability. 

  

	12.5	 Where any New Shares are allotted by way of capitalisation to the Nominee in respect of any Participant’s
Plan Shares, such New Shares shall form part of that Participant’s Plan Shares and shall be deemed to have been appropriated at the same time as the Participant’s Plan Shares in respect of which they are allocated. 

 

	12.6	 In the event of any variation of the share capital of the Company or a demerger, special dividend or other
similar event which affects the market price of shares to a material extent, the Board may make such adjustments as it considers appropriate to the number of Shares comprised in an Award or, where any Award has Vested but no Shares have been
transferred or allotted after such Vesting, the number of Shares which may be so transferred or allotted. 

  

	13.	 RECONSTRUCTION AND TAKEOVER 

 

	13.1	 If there is a Reconstruction or Takeover affecting Plan Shares, the Participants shall be notified of such
event by the Nominee and any Participant may give notice to the Nominee instructing him on the action to be taken (and, where appropriate, exercise any right to elect to receive any particular form of consideration available thereunder) in respect
of any of his Plan Shares. 

  

	13.2	 If there is a Reconstruction or Takeover affecting Plan Shares, the consideration received thereunder shall (so
far as it consists of cash or securities other than New Shares) be treated as the proceeds of a disposal under Rule 18.1 and so far as it consists of New Shares be held by the Nominee as Plan Shares subject to the Rules mutatis mutandis as if the
same were the Shares in respect of which they are issued, or which they otherwise represent. 

  
 Confidential 

-18- 

			
	

	  	CLIFFORD CHANCE LLP

  

	13.3	 If notices to acquire compulsorily any Plan Shares are issued under sections 979 to 985 of the Companies Act
2006 by another company for a consideration consisting of cash and/or shares, the Participants concerned shall be entitled to receive notification thereof from the Nominee as soon as practicable after receipt of such notice(s) by the Nominee and to
give notice of their instructions to the Nominee in relation to such consideration. The provisions of Rules 13.1, 13.2 and 16 shall apply mutatis mutandis so far as relevant. 

 

	13.4	 If any event occurs within any of Rules 13.1 to 13.3, then the Company shall determine the treatment of any
Free Shares and/or Matching Shares that have not yet Vested from the following:- 

  

	 	(a)	 where the consideration under the event in question consists of cash or securities other than New Shares, any
such Awards will lapse to the extent that they have not Vested at the time of the event in question; or 

  

	 	(b)	 to the extent that the consideration consists of New Shares, then any such Awards will continue to Vest on
their existing terms, subject to the approval of the Board; or 

  

	 	(c)	 any Free Shares and/or Matching Shares will Vest on the date of such event but only pro rata to the proportion
of the Vesting Period that has elapsed since the Award Date and the balance of such Free Shares and/or Matching Shares will thereupon automatically lapse; or 

  

	 	(d)	 any other treatment determined by the Board. 

 

	13.5	 If an order is made for the winding up of the Company, then any Free Shares and/or Matching Shares that have
not yet Vested at that time shall thereupon automatically Vest. 

  

	14.	 VOTING RIGHTS AND DIRECTIONS 

 

	14.1	 A Participant may direct the Nominee to exercise any voting rights attaching to such Participant’s Plan
Shares in accordance with such Participant’s wishes. The Nominee shall not be entitled to vote on a show of hands in respect of Plan Shares unless all directions received from Participants in respect of the particular resolution are identical.
The Nominee shall not in any circumstances be under an obligation to call for a poll. If there is a poll the Nominee shall vote only in accordance with the directions of Participants. The Nominee shall not exercise voting rights in respect of Plan
Shares in the absence of any such directions. The Nominee may not vote in respect of Shares (if any) which have not been Awarded pursuant to the Plan. 

  

	14.2	 Subject to the specific provisions of Rule 12, the Nominee shall deal with any right conferred in respect of
any of those Shares to be allotted other shares, securities or rights of any description only pursuant to a direction given by notice by or on behalf of the Participant (or any person in whom the beneficial interest in that Participant’s Shares
is for the time being vested). 

  
 Confidential 

-19- 

			
	

	  	CLIFFORD CHANCE LLP

  

	15.	 SCRIP DIVIDENDS 

 

	15.1	 Subject to Rule 7, this Rule 15 applies where the holders of any class of shares of which some are Plan Shares
are offered the right to elect to receive shares, credited as fully paid in whole or in part, in lieu of a cash dividend. Within five Dealing Days or such other period as the Nominee may decide before the closing of the offer, the Participant may:

  

	 	(a)	 instruct the Nominee to elect to receive shares; or 

 

	 	(b)	 instruct the Nominee to elect to receive cash, 

which instructions may be of particular or of general application and relate to Plan Shares Awarded before and after the relevant date of the
scrip dividend. If neither Rule 7.1(a) nor Rule 7.1(b) applies the Nominee shall notify Participants of their right to elect for shares or cash. 
  

	15.2	 Any shares taken up by the Nominee on behalf of any Participant under this Rule shall not form part of the
Participant’s Plan Shares to which they relate and they shall belong to the Participant, and the Nominee shall take all reasonable steps to procure that the Shares so acquired are vested in the Participant without delay. 

 

	16.	 FRACTIONAL ENTITLEMENTS 

 

	16.1	 Where a company makes an offer or invitation conferring any rights upon its members including the Nominee to
acquire, against payment, additional securities in that company or where that company allots any new securities by way of capitalisation, the Nominee shall allocate such rights or securities amongst the Participants concerned on a proportionate
basis and, if such allocation shall give rise to a fraction of a security or a transferable unit thereof (in this Rule a “unit”), shall round such allocation down to the next whole unit and the Nominee shall aggregate the fractions
not allocated and use his best endeavours to sell any rights or units which are not allocated and distribute the net proceeds of sale (after deducting therefrom any expenses of sale and any taxation which may be payable in respect thereof)
proportionately among the Participants whose allocation was rounded down, provided that any sum of less than £3 otherwise distributable to a particular Participant may be retained by the Nominee. 

 

	16.2	 In any circumstances in which the Nominee receives New Shares which form part of a Participant’s Plan
Shares the Nominee shall allocate the New Shares to the Participant by reference to the relative Award Dates of his Plan Shares to which they relate and, if any such allocation should give rise to a fraction of a New Share, the Nominee shall round
such allocation up or down to the next whole unit as he in his discretion thinks fit. 

  

	17.	 CIRCULARS AND NOTICES 

The Company may provide or make available (or procure that the Company’s registrars may provide or make available) to a Participant upon
request copies of any notices, circulars and other documents sent to shareholders of the Company. 

  
 Confidential 

-20- 

			
	

	  	CLIFFORD CHANCE LLP

  

	18.	 DISPOSALS AND PAYMENTS 

 

	18.1	 Upon receipt of a sum of money being (or being part of) the proceeds of any disposal or Capital Receipt in
respect of any Plan Shares, the Nominee shall account as soon as reasonably practicable to the Participant for any balance remaining in their hands and relating to such Plan Shares by paying the same to the Participating Company or Subsidiary (if
any) by which he is employed, PROVIDED THAT any sum of less than £3 distributable to a particular Participant may be retained by the Nominee 

  

	18.2	 Any Participating Company or Subsidiary to which the Nominee pays or accounts for any part of any such sum as
is referred to in Rule 18.1 shall forthwith account to the Participant for the balance remaining in its hands. 

  

	19.	 AMENDMENT OF THE PLAN 

 

	19.1	 Subject to clause 19.2, the Board shall at any time be entitled by resolution to amend all or any of the
provisions of the Plan. 

  

	19.2	 Subject to clause 19.3, the provisions concerning eligibility, individual and overall limits, the basis for
determining a Participant’s entitlement to, and the terms of, Shares or cash provided under the Plan, the adjustments that may be made in the event of any variation of the share capital of the Company and the terms of this Rule 19.2 shall not
be amended to the advantage of existing or future Participants without the prior approval by ordinary resolution of the members of the Company in general meeting. 

 

	19.3	 Clause 19.2 shall not apply to any minor amendment to benefit the administration of the Plan, to comply with or
take account of the provisions of any proposed or existing legislation, or to obtain or maintain favourable taxation, exchange control or regulatory treatment of the Company, any Subsidiary or any Participant. 

 

	19.4	 No amendment shall be made to the Plan which: 

 

	 	(a)	 would materially and adversely affect the beneficial interests of Participants in Shares already Awarded to
them under the Plan; or 

  

	 	(b)	 would cause the Plan to cease to be an employees’ share scheme within the meaning of section 1166 of the
Companies Act 2006. 

  

	20.	 DISPUTES 

The decision of the Board in any dispute or question arising from or relating to the Plan shall be final and conclusive (and binding on all
persons). 
  

	21.	 NOTICES 

  

	21.1	 The Nominee shall not be bound to act upon any notice given by or on behalf of a Participant or any person in
whom the beneficial interest in his Plan Shares is for the time being vested pursuant to the Plan unless such notice is received by the Nominee in writing signed by the relevant person PROVIDED THAT: 

  
 Confidential 

-21- 

			
	

	  	CLIFFORD CHANCE LLP

  

	 	(a)	 “in writing” may include writing on or transmitted via the screen of a visual display unit or other
similar device, including facsimile, but only where such electronic writing or transmission is lawful in the jurisdictions of the giver and receiver of the notice; and 

 

	 	(b)	 the Nominee or the Board as appropriate may specify from time to time that a notification may be given by such
alternative means as may be acceptable to the Nominee or the Board. 

  

	21.2	 Any notice which the Nominee is required or may desire to give to any Eligible Employee or Participant pursuant
to the Plan shall be in writing PROVIDED THAT: 

  

	 	(a)	 “in writing” may include writing on or transmitted via the screen of a visual display unit or other
similar device, including facsimile, but only where such electronic writing or transmission is lawful in the jurisdictions of the giver and receiver of the notice; and 

 

	 	(b)	 the Nominee or the Board as appropriate may specify from time to time that a notification may be given by such
alternative means as may be acceptable to the Nominee or the Board 

 and notice is sufficiently given if delivered to the
Eligible Employee personally or sent by post pre-paid addressed to the Eligible Employee or Participant at his address last known to the Nominee (including any address supplied by the relevant Participating
Company or any Subsidiary as being his address) or in an electronic communication to their usual business address or if sent through the Group’s internal postal service. 
  

	22.	 TERMS OF EMPLOYMENT 

 

	22.1	 Nothing in the Plan shall in any way be construed as imposing upon a Participating Company a contractual
obligation as between that Participating Company and an employee to contribute or to continue to contribute to the Plan. 

  

	22.2	 In no circumstances shall any person who has ceased to be an employee of any member of the Group by reason of
dismissal or otherwise howsoever or who is under notice of termination of his employment be entitled to claim as against any member of the Group or the Nominee any compensation for or in respect of any consequential loss he may suffer by reason of
the operation of the terms of the Plan. 

  

	22.3	 The issuing of an invitation to an Eligible Employee to participate in the Plan and the grant of any Award
under the Plan does not imply that any further invitations or grants will be made nor that a Participant has any right to receive any such invitation or be granted any further Awards in the future. 

 

	23.	 THIRD PARTIES 

 

	23.1	 No third party has any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of the
Plan. 

  
 Confidential 

-22- 

			
	

	  	CLIFFORD CHANCE LLP

  

	24.	 BENEFITS NOT PENSIONABLE 

Benefits provided under the Plan shall not be pensionable. 
  

	25.	 DATA PROTECTION 

If a Participant is employed outside the European Economic Area and consent is needed for the collection, processing or transfer of their
personal data under applicable local law, by participating in this Plan, the Participant gives their consent for the purposes of the Plan. For the purposes of compliance with the General Data Protection Regulation (EU) 2016/679, the Company will
separately provide a Participant with information on the collection, processing and transfer of their personal data, including the grounds for processing. 
  

	26.	 GOVERNING LAW 

The Plan and all Awards shall be governed by and construed in accordance with the law of England and Wales and the Courts of England and Wales
have exclusive jurisdiction to hear any dispute. 

  
 Confidential 

-23- 

			
	

	  	CLIFFORD CHANCE LLP

  

SCHEDULE 1 - ITALIAN SUB-PLAN 

 

	1.	 PURPOSE 

The provisions of this Italian Sub-Plan shall prevail over those of the Plan insofar as Awards are made
to Italian Participants. 
  

	2.	 DEFINITIONS 

  

	2.1	 The words and expressions not specifically defined in this Italian
Sub-Plan shall have the meaning attributed to them in the Plan. 

  

	2.2	 In this Italian Sub-Plan, the following words and expressions have the
following meanings: 

 “Holding Period” mean, in relation to an Award of Matching Shares made to an
Italian Participant, a period of at least three years starting on the day immediately after the end of the Vesting Period during which the Italian Participant is a shareholder of the Company but undertakes not to sell or otherwise dispose of his
Matching Shares; 
 “Italian Participant” means an Eligible Employee who is tax resident in Italy and to whom an Award has
been granted. 
  

	3.	 HOLDING PERIOD  

 

	3.1	 The Board shall specify a Holding Period in respect of each Award of Matching Shares granted to an Italian
Participant. Such Holding Period shall be specified in the Partnership Share Agreement PROVIDED THAT: 

  

	 	(a)	 the Board may specify different Holding Periods from time to time provided that such Holding Period is at least
three years; 

  

	 	(b)	 unless otherwise determined by the Board, the Holding Period must be the same for all Awards of Matching Shares
granted to Italian Participants on a particular date; 

  

	 	(c)	 unless otherwise specified by the Board, the Holding Period shall be three years; and 

 

	 	(d)	 if an Italian Participant dies, the Board may, in its absolute discretion, allow his personal representatives
to sell or otherwise dispose of his Matching Shares before the end of the Holding Period. 

  

	3.2	 If a Tax Liability arises in relation to any Award of Matching Shares held by an Italian Participant before the
end of the Holding Period, the Italian Participant must have entered into arrangements acceptable to the Board that the relevant member of the Group will receive the amount of such Tax Liability but such arrangements must not include the sale or
disposal of any of the Italian Participant’s Matching Shares. 

  
 Confidential 

-24- 

			
	

	  	CLIFFORD CHANCE LLP

  

SCHEDULE 2 – US SUB-PLAN 

SPECIAL SCHEDULE IN RELATION TO THE OPERATION OF THE PLAN FOR PARTICIPANTS WHO ARE SUBJECT TO TAXATION IN THE UNITED STATES OF AMERICA

  

	1.	 This Special Schedule amends, modifies and supplements the Plan. 

 

	2.	 The purpose of this Special Schedule is to ensure that Awards of RSUs made under the Plan will comply with the
short-term deferral exception under section 409A of Title 26 of the United States Code (the “Internal Revenue Code”). Notwithstanding the foregoing, this Special Schedule should also be interpreted and applied in a manner consistent
with other legal requirements under laws in relevant jurisdictions, including but not limited to applicable securities laws. 

  

	3.	 For the purposes of this Special Schedule, “US Participant” shall mean any individual who is,
or may become, a US taxpayer (including a US citizen, Green cardholder or any employee who is resident in the US for tax purposes) prior to the grant of an Award under this Plan. In the event that a Participant becomes a US taxpayer after the grant
of an Award, such Award is modified in a manner consistent with this Special Schedule. 

  

	4.	 The provisions of this Special Schedule shall apply in relation to the operation of the Plan for US
Participants, notwithstanding any other provision of the Plan. 

  

	5.	 Except to the extent expressly amended by this Special Schedule, the terms and conditions of the Plan are
hereby confirmed and shall remain in full force and effect. 

  

	6.	 The Plan and this Special Schedule shall be read and be construed as one document and this Special Schedule
shall be considered to be part of the Plan and, without prejudice to the generality of the foregoing, and where the context so allows, references in the Plan to “the Plan”, howsoever expressed, shall be read and construed as references to
the Plan as amended, modified and supplemented by this Special Schedule. 

  

	7.	 All terms and expressions used in this Special Schedule and which are defined or construed in the Plan, but are
not defined or construed in this Special Schedule, shall have the same meaning and construction in this Special Schedule, unless the context otherwise requires. Any reference in this Special Schedule to the Plan shall refer to the Plan as from time
to time amended, modified or supplemented, and any document which amends, modifies or supplements the Plan. 

  

	8.	 Subject to paragraph 9 below, when any RSU held by a US Participant Vests, the Shares subject to the RSU in
question shall be transferred to the US Participant within 60 days of Vesting. 

  

	9.	 To the extent that a transfer of Shares in accordance with paragraph 8 above would contravene the Market Abuse
Regulation, such transfer will take place as soon as administratively practicable following the earliest date on which transfer would not contravene the Market Abuse Regulation and not later than thirty days from this date. 

  
 Confidential 

-25- 

			
	

	  	CLIFFORD CHANCE LLP

  

	10.	 In the case of a US Participant ceasing to be a director or employee for any reason other than those specified
in Rule 10.1 (a), (c), (d), (e), (f) and (g), all of the US Participants Shares held in the Plan and RSUs shall be forfeited. 

  

	11.	 The Board may amend any of the provisions of this Special Schedule to take account of a change in US
legislation, in particular in relation to section 409A of the Internal Revenue Code. 

  

	12.	 Notwithstanding anything to the contrary in the Plan or this Special Schedule or elsewhere, if a US Participant
is a “specified employee” as determined pursuant to Section 409A of the Internal Revenue Code and regulations issued thereunder as of the date of such US Participant’s “separation from service” (within the meaning of
Section 409A of the Internal Revenue Code and regulations issued thereunder) and any Award (other than Partnership Shares) is determined to be “deferred compensation” (within the meaning of Section 409A of the Internal Revenue
Code and regulations issued thereunder) and is paid or settled upon such separation from service, then any such payment or settlement shall only be paid or settled on the first business day of the seventh calendar month following the month in which
the US Participant’s “separation from service” occurs. 

  
 Confidential 

-26-edsa_ex101

Exhibit 10.1

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE
EXHIBIT

BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE
COMPETITIVE

HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

 

 

 

 

 

EXCLUSIVE LICENSE AGREEMENT

 

by and between

 

Dr. Saul Yedgar

 

and

 

EDESA BIOTECH RESEARCH INC.

 

March 16, 2021

 

 

 

 

 

 

 

 

 

TABLE
OF CONTENTS

 

	
 

	

Page

	

Article 1 DEFINITIONS

	

1

	

Article 2
SCOPE  

	

7

	

2.1

	

Scope.

	

7

	

Article 3 PRODUCT DEVELOPMENT AND
COMMERCIALIZATION.

	

7

	

3.1

	

Overview.

	

7

	

3.2

	

Conduct
of Development and Commercialization.

	

7

	

3.3

	

Development
Plan

	

7

	

3.5

	

Rights
to Sublicense.

	

8

	

Article 4 MANUFACTURE AND SUPPLY

	

9

	

4.1

	

Responsibility
for Manufacturing and Supply.

	

9

	

Article 5 REGULATORY

	

9

	

5.1

	

Regulatory
Obligations.

	

9

	

5.2

	

Safety
Reporting.

	

9

	

5.3

	

Recalls.

	

10

	

5.4

	

Pricing
and Reimbursement.

	

10

	

Article 6 PAYMENTS

	

10

	

6.1

	

Milestone
Payments.

	

10

	

6.2

	

Product
Royalties.

	

11

	

6.3

	

Reports;
Payment of Royalty.

	

11

	

6.4

	

Audits.

	

12

	

6.5

	

Payment
Exchange Rate.

	

13

	

6.6

	

Tax
Withholding.

	

13

	

6.7

	

Late
Payments.

	

13

	

Article 7 LICENSES; EXCLUSIVITY

	

13

	

7.1

	

Exclusive
License and Right to Sublicense.

	

13

	

7.2

	

No
Implied Licenses.

	

14

	

Article 8 CONFIDENTIALITY; PUBLICATION

	

14

	

8.1

	

Nondisclosure
Obligation.

	

14

	

8.2

	

Publicity;
Use of Names.

	

15

	

Article 9 REPRESENTATIONS AND WARRANTIES

	

16

	

9.1

	

Representations
and Warranties of LICENSOR.

	

16

	

9.2

	

Representations
and Warranties and Covenants of EDESA.

	

17

	

9.3

	

Representations
and Covenants of Both Parties.

	

17

	

9.4

	

No
Other Representations or Warranties.

	

18

 

-i-

 

 

TABLE OF CONTENTS 

(continued)

	
 

	

Page

	

Article 10 INDEMNIFICATION

	

18

	

10.1

	

General
Indemnity By EDESA.

	

18

	

10.2

	

Limitation
of Liability.

	

19

	

10.3

	

Insurance.

	

20

	

Article 11 INVENTIONS; PATENT PROVISIONS

	

20

	

11.1

	

Ownership
of Intellectual Property.

	

20

	

11.2

	

Patent
Prosecution

	

20

	

11.3

	

Fees

	

20

	

11.4

	

Enforcement.

	

20

	

11.5

	

Defense.

	

21

	

Article 12 TERM AND TERMINATION

	

22

	

12.1

	

Term.

	

22

	

12.2

	

Termination
for Cause.

	

22

	

12.3

	

Termination
Without Cause.

	

22

	

12.4

	

Effect
of Termination.

	

22

	

12.5

	

Survival.

	

25

	

Article 13 MISCELLANEOUS

	

25

	

13.1

	

Force
Majeure.

	

25

	

13.2

	

Assignment.

	

25

	

13.3

	

Severability.

	

25

	

13.4

	

Notices.

	

26

	

13.5

	

Applicable
Law and Litigation.

	

26

	

13.6

	

Entire
Agreement; Amendments.

	

27

	

13.7

	

Independent
Contractors.

	

27

	

13.8

	

Waiver.

	

27

	

13.9

	

Cumulative
Remedies.

	

27

	

13.10

	

Waiver
of Rule of Construction.

	

27

	

13.11

	

Further
Assurances.

	

27

	

13.12

	

Construction.

	

28

	

13.13

	

Currency.

	

28

	

13.14

	

Dispute
Resolution.

	

28

	

13.15

	

Statute
of Limitations.

	

38

	

13.16

	

Injunctive
and Other Interim Relief.

	

30

	

13.17

	

Execution
in Counterparts; Facsimile Signatures.

	

30

 

 

-ii-

 

 

EXCLUSIVE LICENSE AGREEMENT

 

This
Agreement (“Agreement”), effective as of March
16, 2021 (“Effective
Date”), is entered into by and between Saul Yedgar, an
individual with principal residence at [___________]
(“LICENSOR”),
and Edesa Biotech Research Inc., an Ontario corporation with its
principal office at 100 Spy Court, Markham, Ontario, L3R 5H6
(“EDESA”).
LICENSOR and EDESA may be referred to herein individually as a
“Party” or
collectively as the “Parties”. Reference to a Party
shall be deemed to include that Party’s Affiliates.
[Principal residence of LICENSOR
omitted.]

 

RECITALS:

 

A. 

LICENSOR owns the
rights to certain know-how, patents and data relating to
formulations containing Di-Palmitoyl Phosphatidyl-Ethanolamine
(DPPE)-conjugated Hyaluronic Acid (HA), or its derivatives (the
“Products”)
developed by LICENSOR.

 

B. 

EDESA is a
pharmaceutical company having expertise in the discovery,
development, manufacturing and commercialization of innovative
human pharmaceutical products.

 

C. 

EDESA and LICENSOR
desire to enter into an agreement under which EDESA will obtain
exclusive rights to develop and commercialize the Products for
therapeutic, prophylactic and diagnostic uses in all applications
other than those covered in the Yissum License Agreement (as
defined below) (the “Field”).

 

In
consideration of the foregoing premises and the mutual covenants
herein contained, the Parties hereby agree as follows:

 

 

ARTICLE 1

DEFINITIONS

 

Unless
specifically set forth to the contrary herein, the following terms,
whether used in the singular or plural, shall have the respective
meanings set forth below:

 

1.1 

“Adverse Event” shall mean any
undesirable medical occurrence in a patient or clinical
investigation subject administered the Product that must be
reported to the relevant Regulatory Authority and which does not
necessarily have to have a causal relationship with the Product, or
the equivalent of the foregoing under Applicable Law in the
relevant jurisdiction.

 

1.2 

“Affiliate” means with respect to a
Party, any person or entity controlling, controlled by or under
common control with such Party. For purposes of this Section 1.2
only, “control”
shall mean: (a) in the case of a corporate entity, direct or
indirect ownership of fifty percent (50%) or more of the stock or
shares having the right to vote for the election of directors of
such corporate entity; and (b) in the case of an entity that is not
a corporate entity, the possession, directly or indirectly, of the
power to direct, or cause the direction of, the management or
policies of such entity, whether through the ownership of voting
securities, by contract or otherwise.

 

 

-2-

 

1.3 

“Applicable Law” means the laws,
rules, statutes, orders, ordinances, regulations, written guidance
and written guidelines having binding effect, and other written
requirements of any Governmental Authority that having binding
effect and may be in effect from time to time and that are
applicable to a Party or a Party’s activities under this
Agreement.

 

1.4 

“Calendar Quarter” means the
respective periods of three (3) consecutive calendar months ending
on March 31, June 30, September 30 and December 31.

 

1.5 

“Calendar Year” means the
respective periods of twelve (12) months commencing on January 1
and ending on December 31.

 

1.6 

“Claimant” has the meaning set
forth in Section ‎13.15.

 

1.7 

“Clinical Material(s)” means the
Product formulated in accordance with the Specifications and
Applicable Law in the relevant jurisdiction: (a) for preclinical
activities; and (b) for administration to subjects in Clinical
Trials.

 

1.8 

“Clinical Trial(s)” means clinical
trials (as defined in the Applicable Law in the relevant
jurisdiction) with respect to the Product in the
Field.

 

1.9 

“Commercialization” or
“Commercialize”
means activities undertaken after obtaining Regulatory Approval
relating specifically to the launch, promotion, marketing, sales
force recruitment, pricing determination, sale, use and
distribution of a pharmaceutical product and post-launch medical
activities, including: (a) manufacturing and distribution for
commercial sale, (b) strategic marketing, sales force detailing,
advertising, and market and product support; (c) medical education
and liaison; (d) all customer support and product distribution,
invoicing and sales activities; (e) all post-Regulatory Approval
regulatory activities, including those necessary to maintain
Regulatory Approvals; (f) target product profile, pricing,
formulary and reimbursement related activities including pricing
and reimbursement approvals; and (g) organizing formulary access
and drug distribution.

 

1.10 

“Confidential Information” has the
meaning set forth in Section ‎8.1.

 

1.11 

“Control,” “Controls” or “Controlled by” means (except as
used in Section 1.2), with respect to any item of or right under
the Licensed Technology, the ability of a Party (whether through
ownership or license, other than pursuant to this Agreement) to
grant access to, or a license or sublicense of, such item or right
as provided for herein without violating the terms of any agreement
or other arrangement with any Third Party existing at the time such
Party would be required hereunder to grant the other Party such
access or license or sublicense.

 

1.12 

“demand for arbitration” has the
meaning set forth in Section ‎13.15.

 

1.13 

“Develop” or “Development” or
“Developing”
means research, discovery, process development, manufacturing for
preclinical and clinical uses, preparation for drug reimbursement,
preparation and initiation of medical education and liaison
activities and preclinical and clinical drug or biological
development activities, including test method development and
stability testing, toxicology, formulation, quality
assurance/quality control development, statistical analysis,
preclinical and clinical studies and regulatory affairs, Regulatory
Approval and registration, in each case, of a Product for use in
the Field.

 

 

-3-

 

1.14 

“DTAA” means the Convention between
the Government of Canada and the Government of the State of Israel
for the Avoidance of Double Taxation and the Prevention of Fiscal
Evasion with respect to Taxes on Income.

 

1.15 

“EDESA Data” means any scientific,
technical, clinical or regulatory information, results and data of
any type whatsoever, in any tangible or intangible form whatsoever,
including databases, safety information, filings, practices,
methods, techniques, specifications, formulations, formulae,
knowledge, know-how, skill, experience, test data including
pharmacological, medicinal chemistry, biological, chemical,
biochemical, toxicological data, data and results arising from the
conduct of Clinical Trials, analytical and quality control data,
stability data, studies and procedures, and manufacturing process
and development information, results and data that: (a) are
conceived, discovered, invented, made or first reduced to practice
by, or on behalf of, EDESA on or after the Effective Date; and (b)
are related to the Product (or a composition containing the Product
or the manufacturing or use of the Product).

 

1.16 

“EMA” means the European Medicines
Agency or any successor agency thereto.

 

1.17 

“FDA” means the United States Food
and Drug Administration or any successor agency
thereto.

 

1.18 

“Field” has the meaning ascribed to
it in the recitals.

 

1.19 

“First Commercial Sale” means, with
respect to a Product in the Field, the first sale to a Third Party
for end use or consumption of such Product in the Field in a
country in the Territory after Regulatory Approval of such Product
in the Field has been granted by the Regulatory Authority of such
country, but excluding sales made under special access or similar
program authorized by an applicable Regulatory
Authority.

 

1.20 

“Governmental Authority” means any
supranational, national, federal, state, provincial, country, city
or local government or any agency, department, authority, court, or
other instrumentality thereof, including any Regulatory
Authority.

 

1.21 

“IFRS” means International
Financial Regulatory Standards as the same may be in effect from
time to time.

 

1.22 

“IND” means an Investigational New
Drug application in the United States, a Clinical Trial Application
in Canada, or a foreign equivalent application or submission for
approval to conduct human clinical investigations filed with or
submitted to a Regulatory Authority in conformance with the
requirements of such Regulatory Authority.

 

1.23 

“Indication” means any separate and
distinct disease (or stage of disease), disorder or medical
condition in humans or non-human animals which a Product is
intended to treat, prevent, diagnose, monitor or ameliorate and
which, for a Product candidate, is intended to be reflected in the
labeling for such Product as an approved indication, and which, for
an approved Product, is reflected in the labeling for such
Product.

 

 

-4-

 

1.24 

“Information” means any and all
scientific, pre-clinical, clinical, regulatory, manufacturing,
marketing, financial and commercial information and data related to
the Product, in any tangible or intangible form.

 

1.25 

“Knowledge” shall mean actual
knowledge of any of the current officers of the Party gained in the
regular course of the relevant Party's business.

 

1.26 

“Licensed Technology”
means:

 

(a)            

all
Patents;

 

(b) 

any proprietary
scientific, technical, clinical or regulatory information, results
and data of any type whatsoever, in any tangible or intangible form
whatsoever, including databases, safety information, filings,
practices, methods, techniques, specifications, formulations,
formulae, knowledge, know-how, skill, experience, test data
including pharmacological, medicinal chemistry, biological,
chemical, biochemical, toxicological data, clinical trial data,
analytical and quality control data, stability data, studies and
procedures (including any data submitted as part of the IND), and
manufacturing process and development information, results and
data; and

 

(c) 

any proprietary
biological, chemical or physical materials (including any active
pharmaceutical ingredient);

 

and in
the case of items listed in paragraphs (a), (b) and (c) only, that
are Controlled by LICENSOR as of the Effective Date or at any time
during the Term and: (i) related directly and only to the Product
(or a composition containing the Product or the manufacturing or
use of the Product); or (ii) necessary for EDESA to exercise the
rights licensed to it under this Agreement or to perform its
obligations under this Agreement.

 

1.27 

LICENSOR Indemnitee(s)” has the
meaning ascribed to it in Section ‎10.1

 

1.28 

“NDA” or “New Drug Application” means an
application submitted to FDA pursuant to 21 U.S.C. § 505(b) or
a Canadian or foreign equivalent application or submission to a
Regulatory Authority under Applicable Law in the relevant
jurisdiction which contains complete details of the manufacture and
testing of a new drug, for purposes of obtaining Regulatory
Approval for such new drug in the applicable jurisdiction, for a
particular Indication, and also includes a Biologics License
Application.

 

1.29 

“Net Sales” means the gross amount
invoiced, billed and
collected by EDESA or
its Affiliates to unrelated Third Parties (excluding any
Sublicensee) for the Product in the Territory, less:

 

(a) 

Trade, quantity and
cash discounts actually allowed or paid;

 

 

-5-

 

(b) 

Commissions,
discounts, refunds, rebates (including wholesaler fees),
chargebacks, retroactive price adjustments, and any other
allowances actually allowed or paid which effectively reduce the
net selling price;

 

(c) 

Actual Product
returns and allowances;

 

(d) 

Any sales, use,
excise, value added taxes or similar taxes measured by the billing
amount, when included in billing;

 

(e) 

Any freight,
postage, shipping, and insurance charges related to delivery of the
Product from an applicable warehouse, all to the extent included in
the third party invoices; and

 

(f) 

custom, import and
export duties actually paid.

 

Any
refund or reimbursement of any of the foregoing amounts previously
deducted from Net Sales shall be appropriately credited to Net
Sales, or adjusted through allowances, upon receipt
thereof.

 

For
greater certainty “Net Sales” shall not include sales
or transfers between members of the group comprised of EDESA,
Sublicensees, and their respective Affiliates.

 

In the
event that EDESA or its Affiliates or anyone on their behalf
receives non-monetary consideration for any Product or in the case
of transactions not at arm’s length between EDESA or its
Affiliates and the recipient of the Product, Net Sales shall be
calculated based on the fair market value of such consideration or
transaction, assuming an arm’s length transaction made in the
ordinary course of business.

 

For
greater certainty, provision of Product for the purpose of
conducting Clinical Trials in order to obtain Regulatory Approvals
shall not be deemed to be a sale for the purposes of calculating
Net Sales.

 

Such
amounts shall be determined from the books and records of EDESA or
its Affiliates or Sublicensees, as applicable, maintained in
accordance with US GAAP, consistently applied, except where US GAAP
is not the standard, in which case whatever the accounting standard
is in effect will be applied. EDESA further agrees that in
determining such amounts, it will use EDESA's then current standard
procedures and methodology, including EDESA's then current standard
exchange rate methodology for the translation of foreign currency
sales into U.S. Dollars, consistently applied.

 

1.30 

“Patent(s)” means:

 

(a) 

all patents and
patent applications in any country or supranational jurisdiction;
and

 

 

-6-

 

(b) 

any provisionals,
substitutions, divisions, continuations, continuations in part,
reissues, renewals, registrations, confirmations, reexaminations,
extensions, supplementary protection certificates and the like, of
any such patents or patent applications;

 

that
are Controlled by LICENSOR, as of the Effective Date or at any time
during the Term and that: (i) related to the Product (or a
composition containing the Product or the manufacturing or use of
the Product); or (ii) necessary or useful for EDESA to exercise the
rights licensed to it under this Agreement or to perform its
obligations under this Agreement, including, without limitation,
the patent applications and patents listed in Appendix
A.

 

1.31 

“Products” has the meaning ascribed
to it in the recitals.

 

1.32 

“Regulatory Approval(s)” means all
approvals or authorizations by Regulatory Authorities necessary to
market and sell the Product in the Field in the
Territory.

 

1.33 

“Regulatory Authority” means any
applicable government regulatory authority involved in granting
approvals for the conduct of Clinical Trials or for an NDA in the
Territory, including in the United States, the FDA, and in Canada,
Health Canada.

 

1.34 

“Respondent” has the meaning set
forth in Section ‎13.15(b).

 

1.35 

“Royalties” has the meaning set
forth in Section ‎6.2.

 

1.36 

“Specifications” means the
specifications for the Product as provided by LICENSOR as part of
the Licensed Technology.

 

1.37 

“Sublicensee” means a Third Party
that is granted a sublicense under the licenses granted to a Party
under this Agreement.

 

1.38 

“Sublicensing Fees” has the meaning
set forth in Section ‎6.2.

 

1.39 

“Sublicensing Revenue” means the
net amount of all revenues, royalties, receipts, and monies,
including upfront payments, milestone payments, and license fees,
earned or received by EDESA and its Affiliate(s) from
Sublicensee(s) with respect to the Product.

 

1.40 

“Term” has the meaning set forth in
Section ‎12.1.

 

1.41 

“Territory” means the entire
world.

 

1.42 

“Third Party” means an entity other
than: (a) EDESA and its Affiliates; and (b) LICENSOR and its
Affiliates.

 

1.43 

“United States” means the United
States of America and its territories and possessions, including
the Commonwealth of Puerto Rico and the U.S. Virgin
Islands.

 

 

-7-

 

1.44 

“Yissum License Agreement” means
the Exclusive License Agreement entered into by EDESA and Yissum
Research Development Company of the Hebrew University of Jerusalem
dated June 29, 2016, as amended by the First Amendment to the
Exclusive License Agreement dated April 3, 2017 and the Second
Amendment to the Exclusive License Agreement dated May 7,
2017.

 

ARTICLE 2

SCOPE

 

2.1 

Scope.

 

Pursuant to and
subject to the terms of this Agreement: (a) EDESA will be
exclusively responsible for the Development of the Product in the
Territory in the Field with the goal of obtaining Regulatory
Approval for the Product, and, once Regulatory Approval has been
obtained, for the Commercialization of the Product in the Territory
in the Field; and (b) EDESA will have exclusive rights to Develop
and Commercialize the Product as further set forth in Section
‎3.1, in exchange for royalty and other payments to be made
to LICENSOR as described in ‎Article 6.

 

 

ARTICLE 3

PRODUCT DEVELOPMENT AND COMMERCIALIZATION.

 

3.1 

Overview.

 

From
and after the Effective Date and during the Term, EDESA shall have
full responsibility and authority, at its sole cost and expense,
for the Development and Commercialization of the Product in the
Field in the Territory, including (a) the conduct of all Clinical
Trials and (b) seeking Regulatory Approvals for the Product. Upon
EDESA’s request, LICENSOR will promptly execute such letters
as may be required in order to effect transfer to EDESA of any IND,
for filing with the relevant Regulatory Authorities.

 

3.2 

Conduct
of Development and Commercialization.

 

EDESA
shall use commercially reasonable efforts to Develop and
Commercialize the Product in the Field in the Territory in
accordance with the Development Plan, as defined in Section
‎3.3. For purposes of this Agreement, “commercially
reasonable efforts” means such efforts as would be employed
by EDESA for a product at a similar development stage, having
similar market potential and having similar commercial and
scientific advantages and disadvantages based on conditions then
prevailing. EDESA shall report to LICENSOR through the Development
Plan as to the status of Development and Commercialization of the
Product in the Field.

 

3.3 

Development
Plan

 

a) 

Within sixty (60)
days of the Effective Date, the Parties will meet (in person or
through other means) and work in good faith to create a mutually
agreeable plan for the Development of the Product by EDESA (the
“Development
Plan”), including development targets (the
“Development
Targets”). EDESA shall be responsible for executing
the Development Plan and will allocate the time and resources
required to do so. EDESA shall periodically prepare an update to
the Development Plan and deliver same to LICENSOR within sixty (60)
days following each twelve (12) month anniversary of the execution
of this Agreement and shall keep LICENSOR reasonably informed
concerning the Development Plan, its progress and its results on an
oral basis.

 

 

-8-

 

b) 

The Parties will
meet (in person or through other means) and work in good faith to
amend and adjust the Development Plan as needed, in good faith
judgment, in order to improve EDESA’s ability to meet the
Development Targets. Notwithstanding the foregoing or anything to
the contrary in this Agreement, EDESA shall not be entitled to
change the Development Targets or the time frames for achieving the
Development Targets without LICENSOR’s prior written consent
which shall not be unreasonably withheld. Such consent shall not be required
in connection with a Development Target delayed or revised due to
an action, decision, recommendation or position taken by a
Regulatory Authority to the extent that EDESA continues to actively
and continuously invest the required financial resources to meet
the respective Development Target, as confirmed to LICENSOR in
writing by EDESA’s senior management.

 

c) 

An EDESA
representative and LICENSOR shall meet or conduct a teleconference
(at their election) no less than once every Calendar Year during
the term of this Agreement commencing with the Effective Date, at
locations and times to be mutually agreed upon by the Parties, (i)
to review the progress being made under the Development Plan and
the progress being made in any other research and development
activities conducted by EDESA, its Affiliates and Sublicensees
relating to Products, (ii) to review and agree upon any necessary
or desired revisions to the then current Development Plan, (iii) to
review the progress being made towards fulfilling the Development
Targets and (iv) to discuss intended efforts for fulfilling such
targets.

 

3.5 

Rights
to Sublicense.

 

EDESA
shall have the right to engage Third Parties (each a
“Sublicensee”)
to perform any of its activities or obligations hereunder, provided
that EDESA shall be responsible for ensuring that, prior to any
such engagement, any Sublicensees are subject to an agreement (a
“Sublicense
Agreement”) containing terms and conditions: (i)
specifying that such written agreements terminate upon termination
of this Agreement; (ii) consistent with the relevant terms and
conditions of this Agreement protecting the rights of LICENSOR
under this Agreement including imposing obligations of
confidentiality on each such Sublicensee; (iii) that vest ownership
of any and all inventions developed by such Sublicensee relating to
Products in the course of performing activities under such
sublicense in EDESA; and (iv) that do not impose any payment
obligations or liability on LICENSOR without the prior written
consent of LICENSOR. EDESA shall require each Sublicensee to
provide it with regular written royalty reports that include at
least the detail that EDESA is required to provide to LICENSOR
pursuant to this Agreement. Upon request, EDESA shall provide such
reports to LICENSOR. EDESA shall provide LICENSOR with an executed
copy of each Sublicense Agreement within thirty (30) days of its
execution. Any breach of the terms of this Agreement by a
Sublicensee, including any act or omission by a Sublicensee which
would have constituted a breach of this Agreement had it been an
act or omission by EDESA, shall constitute a breach of this
Agreement by EDESA.

 

 

-9-

 

ARTICLE 4

MANUFACTURE AND SUPPLY

 

4.1 

Responsibility
for Manufacturing and Supply.

 

(a)           EDESA
will be responsible, at its own cost, for the manufacture of
Product including the Clinical Materials. Promptly following the
execution of this Agreement, LICENSOR shall deliver to EDESA copies
of all Information in its possession or Control, including
manufacturing know-how, and any and all original processes,
records, directly related to the manufacture and supply of the
Product including the Clinical Materials in accordance with the
applicable Specifications in its possession or Control, all at
EDESA’s sole cost and expense.

 

(b)           Upon
the request of EDESA, LICENSOR shall promptly ship to EDESA any
unexpired active pharmaceutical ingredient for the Product in its
possession or Control at EDESA’s sole cost and
expense.

 

 

ARTICLE 5

REGULATORY

 

5.1 

Regulatory
Obligations.

 

EDESA
shall be responsible, at its own cost, for, and shall have the sole
right to control, all regulatory activities and strategy associated
with INDs, NDAs and all other submissions for Regulatory Approvals,
all Regulatory Approvals, and the maintenance of such submissions
and Regulatory Approvals, as well as seeking approval for
reimbursement or pricing of a Product in the Territory, in each
case with respect to the Product in the Field, including
communicating and preparing and filing all reports including all
INDs and NDAs with the applicable Regulatory Authorities. LICENSOR
shall reasonably cooperate with EDESA as requested, in preparing
and filing all such reports, and LICENSOR shall provide EDESA with
all available information, including regulatory, technical and
clinical data concerning the Product to enable EDESA to prepare and
file such reports, at EDESA’s sole cost and expense. EDESA
shall pay all governmental fees associated with obtaining and
maintaining any and all Regulatory Approvals including any
establishment license fees of EDESA or Third Parties which must be
paid with respect to facilities used in the manufacture of the
Product by or on behalf of EDESA.

 

5.2 

Safety
Reporting.

 

EDESA
shall be responsible for all regulatory activities relating to the
Product in the Field including: (i) management and monitoring of
safety and Adverse Event/experience information for; (ii)
regulatory reporting; (iii) managing the global safety database for
the Product; and (iv) reviewing and approving of safety information
for inclusion in the Product label in the Territory, including the
costs and expenses thereof.

 

 

-10-

 

5.3 

Recalls.

 

EDESA
shall be responsible for any recall decision and the conduct of any
recall in respect of the Product in the Field, including the costs
and expenses thereof.

 

5.4 

Pricing
and Reimbursement.

 

EDESA
shall be solely responsible for setting the price for the Product
in the Field, and may do so without discussion or consultation with
LICENSOR.

 

 

ARTICLE 6

PAYMENTS

 

6.1 

Milestone
Payments.

 

EDESA
shall immediately notify LICENSOR of the achievement of any of the
following development and commercial milestones, all for the
Products in the Field, and EDESA shall pay to LICENSOR the
milestone payments listed below which shall be due and payable
within forty (40) days after the event for which the payment is due
(or, (i) for milestones based on Net Sales, within forty (40) days
after the end of the Calendar Year with respect to which such
milestone is triggered, (ii) for the first payment with respect to
the execution, upon execution of this Agreement):

 

	

Upon
Execution of this Agreement

	

$[__]

	

Upon
the 6 month Anniversary of the Execution of this
Agreement

	

$[__]

	

Upon
the 1-year Anniversary of the Execution of this
Agreement

	

$[__]

	

Upon
the dosing of the 1st patient into a
Phase 2 Clinical Trial in the Field for the first Indication for
which Regulatory Approval will be sought.

	

$[__]

	

Upon
the dosing of the 1st patient into a
Phase 3 Clinical Trial in the Field for the first Indication for
which Regulatory Approval will be sought.

	

$[__]

	

Upon
receipt of the first NDA for the Product in the Field

	

$[__]

	

Upon
the First Commercial Sale of the Product in the Field in the United
States

	

$[__]

	

First
occurrence of $[__] million in aggregate Net Sales in a Calendar
Year in countries where EDESA or an Affiliate directly
Commercializes the Product

	

$[__]

	

First
occurrence of $[__] million in aggregate Net Sales in a Calendar
Year in countries where EDESA or an Affiliate directly
Commercializes the Product

	

$[__]

	

First
occurrence of $[__] million in aggregate Net Sales in a Calendar
Year in countries where EDESA or an Affiliate directly
Commercializes the Product

	

$[__]

	

First
occurrence of $[__] million in aggregate Net Sales in a Calendar
Year in countries where EDESA or an Affiliate directly
Commercializes the Product

	

$[__]

 

 

-11-

 

For
clarity, the aggregate Net Sales that are taken into account in
order to calculate the achievement of a specific sales threshold
milestone for a Calendar Year cannot also be taken into account in
order to calculate the achievement of additional sales threshold
milestone(s) in that same calendar year. [Milestone payments and amounts of Net Sales
omitted as competitively sensitive
information.]

 

EDESA
shall use commercially reasonable efforts to file an IND for the
Products within the Field within [_________] ([__]) years of the
Effective Date (the “Filing
Period”). In the event EDESA fails to file such IND
within the Filing Period, it shall remit to LICENSOR a fixed
license fee in the amount of [__] US dollars (US$[__]) for each full Calendar Year
following the Filing Period within which such requirement to file
an IND for the Products within the Field remains unfulfilled (the
“Fixed License
Fee”). Such Fixed License Fee shall be paid within
sixty (60) days of the relevant anniversary of the Effective Date.
In the event the afore-said requirement remains unfulfilled after
the Filing Period during a relevant period that is less than a full
Calendar Year, the payment of such Fixed License Fee shall be
pro-rated accordingly. The payment of the Fixed License Fee shall
not derogate from EDESA’s obligations under this Agreement,
including without limitation, the obligations set forth in Section
3 above and further use of commercially reasonable efforts to file
an IND for the Products within the Field following the Filing
Period. [Number of years of Filing
Period and amount of Fixed License Fee omitted as competitively
sensitive information.]

 

6.2 

Product
Royalties.

 

During
the Term, EDESA shall pay to LICENSOR a royalty of [__]% of Net
Sales (“Royalties”) of the Product in the
countries in the Territory where it or an Affiliate directly
Commercializes the Product. EDESA shall pay to LICENSOR an amount
equal to [__]% of Sublicensing Revenue received by EDESA and its
Affiliates (“Sublicensing
Fees”) in the countries in the Territory where it does
not directly Commercialize the Product. [Royalty percentages omitted as competitively
sensitive information.]

 

6.3 

Reports;
Payment of Royalty.

 

Following the
earlier of (a) the First Commercial Sale of the Product and (b)
execution of a Sublicense Agreement with a Sublicensee, EDESA shall
furnish to LICENSOR written reports for each fiscal quarter and
each fiscal year; each such report showing in relation to the
reporting period, as applicable: (i) the Net Sales of the Product
in the Territory and the royalties payable under this Agreement in
respect thereof; and (ii) Sublicensing Revenues received and the
Sublicensing Fees payable under this Agreement in respect thereof.
Reports in respect of a fiscal quarter shall be due on the
thirtieth (30th) day following the close of such fiscal quarter and
annual reports shall be due on the sixtieth (60th) day following
the close of such fiscal year. Royalties and Sublicensing Fees
shown to have accrued by each report shall be due and payable on
the date such report is due. EDESA shall keep complete and accurate
records in sufficient detail to enable the Royalties and
Sublicensing Fees payable hereunder to be determined.

 

 

-12-

 

6.4 

Audits.

 

(a) 

EDESA will keep and
maintain (and to the extent applicable, will cause its Affiliates,
and their respective Sublicensees, assignees and transferees to
keep and maintain) proper and complete records and books of account
in such form and detail as is necessary for the determination of
the amounts payable by EDESA (on behalf of itself and its
Affiliates and their respective Sublicensees, assignees and
transferees) to LICENSOR under this Agreement and for the purposes
of this Agreement.

 

(b) 

Upon the written
request of LICENSOR and not more than once in each Calendar Year,
EDESA shall permit an independent certified public accounting firm
of nationally recognized standing in the United States (that has
been retained on an hourly or flat fee basis and receives no
contingency fee or other bounty or bonus fee) selected by LICENSOR,
at LICENSOR’s expense, to have access during normal business
hours to such of the records of EDESA as may be reasonably
necessary solely to verify the accuracy of the royalty reports
hereunder for any Calendar Year ending not more than thirty six
(36) months prior to the date of such request. This right to audit
shall remain in effect throughout the life of this Agreement and
for a period of three (3) years after the termination of this
Agreement.

 

(c) 

LICENSOR shall
share the accounting firm’s final written report with EDESA
within thirty (30) days of its receipt by LICENSOR. If such
accounting firm identifies a discrepancy by EDESA made during such
period, EDESA shall pay LICENSOR the amount of the discrepancy
within thirty (30) days of the date LICENSOR delivers to EDESA such
accounting firm’s written report so concluding, or as
otherwise agreed upon by the Parties. The fees charged by such
accounting firm shall be paid by LICENSOR unless the underpayment
exceeded ten percent (10%) of the amount owed by EDESA to LICENSOR
for such Calendar Year, in which case, EDESA shall pay to LICENSOR
the reasonable fees charged by such accounting firm which fees
shall not exceed $25,000. EDESA shall pay interest on the amounts
owed to LICENSOR, and said interest shall be calculated as being 2%
greater than the U.S. commercial prime rate as published by the
Wall Street Journal on the date of the first discrepancy identified
in the audit, and shall accrue from the date payments should have
been made.

 

(d) 

EDESA shall include
in each sublicense granted by it pursuant to this Agreement a
provision requiring the Sublicensee to make reports to EDESA, to
keep and maintain records of sales made pursuant to such sublicense
and to grant access to such records by LICENSOR’s independent
accountant to the same extent required of EDESA under this
Agreement.

 

(e) 

LICENSOR shall
treat all financial information subject to review in accordance
with the confidentiality and non-use provisions of this Agreement,
and shall cause its accounting firm to enter into an acceptable
confidentiality agreement with EDESA, its Affiliates or
Sublicensees, as applicable obligating it to retain all such
information in confidence pursuant to such confidentiality
agreement.

 

 

-13-

 

6.5 

Payment
Exchange Rate.

 

All
payments to be made by one Party to the other under this Agreement
shall be made in United States dollars by bank wire transfer in
immediately available funds to a bank account designated in writing
by the Party receiving the payment. In the case of sales outside
the United States, royalty payments by EDESA to LICENSOR shall be
converted to United States Dollars in accordance with the
following: the rate of currency conversion shall be calculated
using a simple average of mid-month and month-end rates as provided
by the spot rate as published by The Wall Street Journal, New York
City Edition for such accounting period.

 

6.6 

VAT;
Tax Withholding.

 

All
amounts to be paid to LICENSOR pursuant to this Agreement are
exclusive of value added tax. EDESA shall add value added tax, if
any, to the extent required by law to all such amounts. If EDESA is
required to withhold any amounts payable hereunder to LICENSOR due
to the applicable laws of Canada, such amount will be deducted from
the payment to be made by EDESA and remitted to the appropriate
taxing authority for the benefit of LICENSOR. EDESA will withhold
only such amounts as are required to be withheld by applicable law
in Canada from which payment is being made. EDESA shall submit to
LICENSOR originals of the remittance voucher and the official
receipt evidencing the payment of the corresponding taxes with the
applicable royalty report. EDESA will cooperate with LICENSOR to
provide such information and records as LICENSOR may require in
connection with any application by LICENSOR to the tax authorities
in Canada or Israel, including attempt to obtain an exemption or a
credit for any withholding tax paid in Canada or Israel. It is
agreed that amounts payable by EDESA to LICENSOR pursuant to
section 6.1 and 6.2 hereof should be exempt based on Article
12(3)(b) of the DTAA, subject to LICENSOR providing a valid
certificate of residency from the Israeli tax authorities no less
than four (4) weeks prior to each applicable payment according to
which LICENSOR is an Israeli tax resident within the meaning of the
DTAA. EDESA shall notify LICENSOR in writing with respect to any
payment to be made by EDESA to LICENSOR under this Agreement a
reasonable time in advance (which shall be no less than four (4)
weeks), and in case that LICENSOR request to delay any payment in
order to provide the valid certificate of residency from the
Israeli tax authorities as aforesaid, then the interest payment
pursuant to Section 6.7 below shall not accrue for such
delay.

 

6.7 

Late
Payments.

 

EDESA
shall pay interest to LICENSOR on the aggregate amount of any
payments that are not paid on or before the date such payments are
due under this Agreement at a rate per annum equal to one percent
(1%) per month, calculated on the number of days such payments are
paid after the date such payments are due and compounded
monthly.

 

 

ARTICLE 7

LICENSES; EXCLUSIVITY

 

7.1 

Exclusive
License and Right to Sublicense.

 

Subject
to the terms and conditions of this Agreement, LICENSOR hereby
grants EDESA and its Affiliates an exclusive, worldwide,
royalty-bearing license, with the right to grant sublicenses in
accordance with Section 3.5 above, to use the Licensed Technology
for the Development and Commercialization of the Product in the
Field in the Territory. For greater certainty, LICENSOR shall
retain the right to use the Licensed Technology in the Territory in
connection with the activities of LICENSOR or its Affiliates that
are unrelated to the Development and Commercialization of the
Product in the Field.

 

 

 

-14-

 

7.2 

No
Implied Licenses.

 

Except
as explicitly set forth in this Agreement, neither Party nor its
Affiliates grants any license, express or implied, under its
intellectual property rights to the other Party. Without limiting
the foregoing, this Agreement and the licenses and rights granted
herein do not and shall not be construed to confer any rights upon
either Party or its Affiliates by implication, estoppel, or
otherwise as to any of the other Party’s or its
Affiliates’ intellectual property, except as otherwise
expressly set forth herein.

 

 

ARTICLE 8

CONFIDENTIALITY;
PUBLICATION

 

8.1 

Nondisclosure
Obligation.

 

(a) 

Except as provided
in this Section ‎8.1, all confidential or proprietary
information disclosed by one Party or any of its Affiliates to the
other Party or any of its Affiliates hereunder in connection with
this Agreement, whether disclosed or provided prior to or after the
Effective Date and whether provided orally, visually,
electronically or in writing, shall be maintained in confidence by
the receiving Party and shall not be disclosed to any Third Party
or used for any purpose except as set forth herein without the
prior written consent of the disclosing Party, until [_____] ([__])
years following the Term of this Agreement, except to the extent
that such Information: [Length of
non-disclosure obligations omitted as competitively sensitive
information.]

 

(i) 

is known by the
receiving Party at the time of its receipt, and not through a prior
disclosure by the disclosing Party under a confidentiality
agreement, as documented by the receiving Party’s business
records;

 

(ii) 

is or becomes part
of the public domain through no fault of the receiving
Party;

 

(iii) 

is subsequently
disclosed to the receiving Party by a Third Party who may lawfully
do so and is not under an obligation of confidentiality to the
disclosing Party; or

 

(iv) 

is developed by the
receiving Party independently of Information received from the
disclosing Party, as documented by the receiving Party’s
business records.

 

All
information disclosed by one Party to the other hereunder, other
than described in Subsections (i) through (iv) above, is
hereinafter referred to as “Confidential Information”. The
Information and the Licensed Technology and the terms and
conditions of this Agreement shall be deemed the Confidential
Information of both Parties.

 

(b) 

Each Party may
disclose Confidential Information of the other Party, without such
other Party's prior written consent, to its and its Affiliates'
directors, officers, employees, agents, consultants, Sublicensees,
suppliers, and other persons or entities who:

 

 

-15-

 

(i) 

need to know such
Confidential Information to assist the Party in fulfilling its
obligations hereunder; and

 

(ii) 

are bound by
written confidentiality and non-use obligations consistent with
those the Party uses to protect its own Confidential
Information.

 

(c) 

Each Party shall
promptly disclose to the other Party the nature and scope of any
breach of this provision by it, or its Affiliates, directors,
officers, employees, agents, consultants, Sublicensees, suppliers,
or other persons or entities permitted hereunder and the steps
taken to contain and address the breach, and shall be liable to the
other Party for any breach of this Article 8 caused by any of the
aforesaid, as applicable.

 

(d) 

Each Party may also
disclose the Confidential Information of the other Party, without
such other Party's prior written consent, to any person, entity,
stock exchange or government or Regulatory Authority to the extent
that the law requires such disclosure, including filings pursuant
to applicable securities or tax laws and regulations. The Party
disclosing such Confidential Information shall take such actions as
are reasonable to preserve the confidentiality of such Confidential
Information, such as requesting confidential treatment. In
addition, EDESA may also disclose LICENSOR's Confidential
Information, without the LICENSOR's prior written consent, to any
person, entity, or government or Regulatory Authority to the extent
that such disclosure is necessary for obtaining, maintaining, or
amending any Regulatory Approvals, seeking approval for
reimbursement or pricing of a Product in the Territory or
satisfying any other regulatory obligation regarding the Product,
or seeking or obtaining consent from a participant in a Clinical
Trial. Each Party may also disclose the Confidential Information of
the other Party, without such other Party's prior written consent,
pursuant to an order of a Regulatory Authority or court of
competent jurisdiction, provided that it: (i) promptly notifies the
other Party of the required disclosure in order to provide such
Party an opportunity to take legal action to prevent or limit such
disclosure and, if asked, reasonably assists the other Party in
pursuing such action; and (ii) shall only disclose the Confidential
Information to the minimum extent required by law.

 

8.2 

Publicity;
Use of Names.

 

(a) 

At its sole
discretion, EDESA may publicly disclose the execution and material
terms of this Agreement and, from time to time, milestones achieved
and activities conducted hereunder. No disclosure of the existence
of, or the terms of, this Agreement or activities conducted
hereunder, may be made by LICENSOR without the prior express
written permission by EDESA. However, that no approval of EDESA
shall be required if a subsequent public disclosure solely
discloses the information that: (1) a milestone under this
Agreement has been achieved and/or any payments associated
therewith have been received; (2) the filing and/or Regulatory
Approval of the NDA with the FDA or the EMA generally has occurred
(provided, however, that specific dates of filing shall not be
disclosed); (3) commercial launch of the Product in any country, or
(4) any information that has previously been approved and disclosed
as permitted by this Section ‎8.2. Except as otherwise
provided in this Section ‎8.2(a), neither Party shall use the
name, trademark, trade name or logo of the other Party or its
employees in any publicity or news release relating to this
Agreement or its subject matter, without the prior express written
permission of the other Party.

 

 

-16-

 

(b) 

Notwithstanding the
terms of this ‎Article 8, either Party shall be
permitted to disclose the existence and terms of this Agreement, to
the extent required, in the reasonable opinion of such
Party’s legal counsel, to comply with applicable laws, rules
or regulations, including the rules and regulations promulgated by
securities law regulatory agencies or any other governmental agency
or applicable stock exchange on which a Party’s stock may be
listed.

 

(c) 

Either Party may
also disclose the existence and terms of this Agreement to its
legal counsel, investment bankers, accountants and advisors, and to
potential Sublicensees, Third Party contractors, investors, lenders
or acquirers, and their legal counsel, investment bankers,
accountants and advisors, in each case under an agreement or in the
case of legal counsel, a professional obligation, to keep the terms
of this Agreement confidential under terms of confidentiality and
non-use substantially similar to the terms contained in this
Agreement and to use such Confidential Information solely for the
purpose permitted pursuant to this Section
‎8.2(c).

 

 

ARTICLE 9

REPRESENTATIONS
AND WARRANTIES

 

9.1 

Representations
and Warranties of LICENSOR.

 

LICENSOR
represents and warrants to EDESA that as of the Effective
Date:

 

(a) 

LICENSOR has the
full right, power and authority to enter into this Agreement, to
perform its obligations under this Agreement, and to grant the
license granted under Section ‎7.1, and the fulfillment of
its obligations and performance of its activities hereunder do not
materially conflict with, violate, or breach or constitute a
default under any material contractual obligation or court or
administrative order by which LICENSOR is bound;

 

(b) 

there are no legal
claims, judgments or settlements against or owed by LICENSOR or to
the Knowledge of LICENSOR, pending legal claims or litigation, in
each case relating to the Product, the LICENSOR or Licensed
Technology;

 

(c) 

all necessary
consents, approvals and authorizations of all government
authorities and other persons required to be obtained by LICENSOR
as of the Effective Date in connection with the execution, delivery
and performance of this Agreement have been obtained;

 

(d) 

LICENSOR is the
exclusive legal and beneficial owner of the Patents listed in
Appendix A.

 

(e) 

LICENSOR Controls
the right, title and interest in and to the Licensed Technology
that it purports to Control, and has the right to grant to EDESA
the licenses that it purports to grant hereunder and has not
granted any Third Party rights that would interfere or be
inconsistent with EDESA’s rights hereunder;

 

 

-17-

 

(f) 

there is no action,
suit, inquiry, investigation or other proceeding ongoing, or to the
Knowledge of LICENSOR, threatened or pending, brought by any Third
Party that alleges the use of the Licensed Technology or the
Development and/or Commercialization of the Product would infringe
or misappropriate the intellectual property or intellectual
property rights of any Third Party (and it has not received any
notice alleging such an infringement or misappropriation). In the
event that LICENSOR becomes aware of any such action or proceeding,
it shall promptly notify EDESA in writing;

 

(g) 

to the Knowledge of
LICENSOR, the use of the Licensed Technology or the Development
and/or Commercialization of the Product will not infringe or
misappropriate the intellectual property or intellectual property
rights of any Third Party;

 

(h) 

LICENSOR does not
have any current knowledge that would cause any of its
representations or warranties to EDESA to be incorrect or
untrue.

 

9.2 

Representations
and Warranties and Covenants of EDESA.

 

EDESA
represents and warrants to LICENSOR that as of the Effective
Date:

 

(a) 

it has the full
right, power and authority to enter into this Agreement, to perform
its obligations under this Agreement and the fulfillment of its
obligations and performance of its activities hereunder do not
materially conflict with, violate, or breach or constitute a
default under any material contractual obligation or court or
administrative order by which EDESA is bound;

 

(b) 

all necessary
consents, approvals and authorizations of all government
authorities and other persons required to be obtained by EDESA as
of the Effective Date in connection with the execution, delivery
and performance of this Agreement have been obtained;

 

(c) 

EDESA does not have
any current knowledge that would cause any of its representations
or warranties to LICENSOR to be incorrect or untrue;

 

(d) 

to the Knowledge of
EDESA, neither EDESA nor any of its Affiliates, nor any of its
employees or agents (i) is debarred, excluded, suspended, proposed
for debarment or otherwise ineligible for participation in any
federal, state or provincial health care program; (ii) has been
convicted of or had a civil judgment rendered against it for
commission of fraud or a criminal offense; and (iii) is presently
indicted for or otherwise criminally or civilly charged by a
governmental entity or agency with commission of any of the
offenses set out in this paragraph;

 

9.3 

Representations
and Covenants of Both Parties.

 

Each
Party shall, and shall cause its Affiliates and agents to, comply
with Applicable Laws, including the United States Food, Drug and
Cosmetics Act and the Food and Drugs Act (Canada) and the
regulations promulgated thereunder, and their foreign
counterparts.

 

 

-18-

 

9.4 

No
Other Representations or Warranties.

 

(a) 

EXCEPT AS EXPRESSLY
STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES
WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL
REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW
OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.

 

(b) 

LICENSOR MAKES NO
EXPRESS OR IMPLIED WARRANTIES THAT ANY FREEDOM TO OPERATE (FTO)
SEARCH WAS MADE OR CONDUCTED BY OR ON BEHALF OF LICENSOR IN
RELATION TO ANY AND ALL PATENTS. IN ADDITION, NOTHING IN THIS
AGREEMENT MAY BE DEEMED A REPRESENTATION OR WARRANTY BY LICENSOR AS
TO THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE,
OF THE LICENSED TECHNOLOGY, WHICH IS BEING LICENSED TO EDESA
STRICTLY ON AN "AS IS" BASIS. LICENSOR HAS NO OBLIGATION, EXPRESS
OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR OTHERWISE ASSUME
RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE, TESTING, MARKETING
OR SALE OF ANY PRODUCT. EXCEPT AS EXPRESSLY STATED IN THIS
AGREEMENT, TO THE EXTENT PERMITTED BY APPLICABLE LAW, NEITHER
LICENSOR, NOR THE REPRESENTATIVES OF LICENSOR SHALL HAVE ANY
LIABILITY WHATSOEVER TO EDESA, AN AFFILIATE OR A SUBLICENSEE, OR TO
ANY THIRD PARTY FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE,
OF ANY KIND OR NATURE WHETHER DIRECT OR INDIRECT, SUSTAINED BY
EDESA, AN AFFILIATE OR A SUBLICENSEE, OR BY ANY THIRD PARTY, FOR
ANY DAMAGE ASSESSED OR ASSERTED AGAINST EDESA, OR FOR ANY OTHER
LIABILITY INCURRED BY OR IMPOSED UPON EDESA OR ANY OTHER PERSON OR
ENTITY, DIRECTLY OR INDIRECTLY ARISING OUT OF OR IN CONNECTION WITH
OR RESULTING FROM THIS AGREEMENT AND/OR THE EXERCISE OF THE
LICENSE, INCLUDING, (i) THE PRODUCTION, MANUFACTURE, USE, PRACTICE,
LEASE, OR SALE OF ANY
PRODUCT; (ii) THE USE OF THE LICENSED TECHNOLOGY; OR (iii) ANY
ADVERTISING OR OTHER PROMOTIONAL ACTIVITIES WITH RESPECT TO ANY OF
THE FOREGOING.

 

 

ARTICLE 10

INDEMNIFICATION

 

10.1 

General
Indemnity By EDESA.

 

EDESA
shall indemnify and hold harmless LICENSOR and its Affiliates
(individually and collectively, the “LICENSOR Indemnitee(s)”) from and
against all losses, liabilities, damages and expenses (including
reasonable legal fees and costs) incurred in connection with any
claims, demands, actions or other proceedings by any Third Party
(individually and collectively, “Losses”) first arising after the
Effective Date to the extent arising from: (a) the Development or
Commercialization of the Product by EDESA or any of its Affiliates
or Sublicensees; (b) the use of the Product manufactured or sold by
EDESA or any of its Affiliates or Sublicensees by any purchasers
thereof including any product liability claim; (c) the use by EDESA
or any of its Affiliates or Sublicensees of the Licensed
Technology.

 

 

-19-

 

10.2 

Defense.

 

If any
such claims or actions are made, the LICENSOR Indemnitee shall be
defended at EDESA's sole expense by counsel selected by EDESA and reasonably acceptable to
the LICENSOR Indemnitee, provided that the LICENSOR Indemnitee may,
at its own expense, also be represented by counsel of its own
choosing. EDESA shall have the sole right to control the defense of
any such claim or action, subject to the terms of this
‎Article 10.

 

10.3 

Settlement.

 

EDESA
may settle any such claim, demand, action or other proceeding or
otherwise consent to an adverse judgment: (a) with prior written
notice to the LICENSOR Indemnitee but without the consent of the
LICENSOR Indemnitee, where the only liability to the Indemnitee is
the payment of money and EDESA makes such payment; or (b) in all
other cases, only with the prior written consent of the LICENSOR
Indemnitee, such consent not to be unreasonably
withheld.

 

10.4 

Notice.

 

The
LICENSOR Indemnitee shall notify EDESA promptly of any claim,
demand, action or other proceeding under Section ‎10.1 and
shall reasonably cooperate with all reasonable requests of EDESA
with respect thereto.

 

10.5 

Permission
by EDESA.

 

The
LICENSOR Indemnitee may not settle any such claim, demand, action
or other proceeding or otherwise consent to an adverse judgment in
any such action or other proceeding or make any admission as to
liability or fault without the express written permission of
EDESA.

 

10.6 

Limitation
of Liability.

 

NEITHER
PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR FOR LOST PROFITS
ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,
REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.
NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION ‎10.6
IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE DAMAGES AVAILABLE FOR
EITHER PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN
‎Article 8.

 

10.7 

Insurance.

 

EDESA
shall maintain in good standing throughout the Term of this
Agreement and for a period of seven (7) years thereafter, product
liability insurance policies in respect of the Product with an
internationally recognized insurer or insurers licensed to do
business in the Territory in an amount of not less than $2.0
million per occurrence, and not less than $2.0 million in the
aggregate, on such terms and conditions as are customary in the
industry. EDESA shall provide proof of such insurance to LICENSOR
within thirty (30) days of the Effective Date and thereafter from
time to time within thirty (30) days of request of proof of such
insurance.

 

 

-20-

 

ARTICLE 11

INVENTIONS; PATENT
PROVISIONS

 

11.1 

Ownership
of Intellectual Property.

 

As
between the Parties, LICENSOR shall remain the sole and exclusive
owner of the Licensed Technology. EDESA shall be the sole and
exclusive owner of all patents, trademarks, know-how, data and
other intellectual property that is conceived, discovered,
invented, made or first reduced to practice by, or on behalf of,
EDESA on or after the Effective Date, including all improvements,
variations, modifications or enhancements of the Licensed
Technology conceived, discovered, invented, made or first reduced
to practice by, or on behalf of, EDESA after the Effective Date and
including the EDESA Data.

 

11.2 

Patent
Prosecution

 

EDESA
will be responsible for preparing, filing, prosecuting and
maintaining the Patents in LICENSOR's name, and may elect to file
applications for such other patents as EDESA deems necessary to
protect the Licensed Technology (“Patent Management”). EDESA will
(a) provide to LICENSOR all material information and documents
received, prepared or filed in connection with the Patents, (ii)
consult with LICENSOR before taking any substantive actions related
to the Patent Management and (iii) consider all comments and
changes suggested by LICENSOR in relation to the Patent Management.
If EDESA intends to abandon, allow to lapse, or not continue the
Patent Management of any Patent, then EDESA will, not less than 60
days before any required action relating to such Patent, notify
LICENSOR and LICENSOR will then have the right, at its option, to
assume the Patent Management of such Patent, in which case such
Patent will be excluded from the Licensed Technology. To assist
EDESA with the Patent Management, LICENSOR will, at the reasonable
request of EDESA, cooperate with EDESA, including provision of
required information, and will execute and deliver documents
(including powers of attorney) and do such other reasonable acts as
EDESA may request.

 

11.3 

Fees

 

EDESA
shall be responsible for all costs associated with the Patent
Management of the Patents listed in Appendices A as of the
Effective Date.

 

11.4 

Enforcement.

 

(a) 

Notice. Each Party shall promptly
provide, but in no event later than forty-five (45) days, the other
with written notice reasonably detailing any known or alleged
infringement or misappropriation of any Licensed
Technology.

 

(b) 

Enforcement of Intellectual Property
Rights. EDESA shall have the right, but not the obligation,
to institute and direct legal proceedings against any Third Party
believed to be infringing or misappropriating or otherwise
violating the Licensed Technology. LICENSOR agrees to co-operate to
the extent reasonably necessary, including signing of all necessary
documents to vest in EDESA the right to start such legal
proceedings, provided that all the direct and indirect costs and
expenses of bringing and conducting the legal proceedings are paid
by EDESA (except for the expenses of LICENSOR’s counsel, if
any). All amounts recovered by EDESA as the result of such legal
proceedings will accrue to the benefit of EDESA, provided that,
after deduction of EDESA’s costs and expenses of legal
proceedings, such amounts awarded as compensation for lost sales
revenue will be included in EDESA’s Sublicensing Revenue if
the action occurs in any country in the territory EDESA does not
directly commercialize the Product and treated as Net Sales in any
country in the Territory that EDESA commercializes the Product upon
which Royalties will be paid to LICENSOR.

 

 

-21-

 

11.5 

Defense.

 

(a) 

Each Party shall
notify the other in writing of any allegations it receives from a
Third Party that the Development or Commercialization of the
Product or use of the Licensed Technology infringes the
intellectual property rights of such Third Party. Such notice shall
be provided promptly, but in no event after more than forty five
(45) days, following receipt of such allegations.

 

(b) 

In the event that a
Party receives notice that it or any of its Affiliates have been
individually named as a defendant in a legal proceeding by a Third
Party alleging infringement of a Third Party’s patents or
other intellectual property right as a result of the Development or
Commercialization of the Product or use of the Licensed Technology,
such Party shall immediately notify the other Party in writing and
in no event notify such other Party later than forty five (45) days
after the receipt of such notice. Such written notice shall include
a copy of any summons or complaint (or the equivalent thereof)
received regarding the foregoing. Each Party shall assert and not
waive the joint defense privilege with respect to all
communications between the Parties reasonably the subject thereof.
In such event, the Parties shall agree how best to mitigate or
control the defense of any such legal proceeding; provided however,
that EDESA shall assume the primary responsibility for the conduct
of the defense of any such claim that is specific to the Field, at
EDESA’s expense, and LICENSOR shall assume the primary
responsibility for the conduct of the defense of any other such
claim, at LICENSOR’s expense. Notwithstanding the foregoing,
LICENSOR may forego assuming the primary responsibility for the
conduct of the defense of any such claim outside the Field, in
which case EDESA shall have the right, but not the obligation, to
assume such primary responsibility at its own expense. The Party
that does not assume primary responsibility for the conduct of the
defense shall have the right, but not the obligation, to
participate and be separately represented in any such suit at its
sole option and at its own expense. Each Party shall reasonably
cooperate with the Party conducting the defense of the claim. If a
Party or any of its Affiliates have been individually named as a
defendant in a legal proceeding relating to the alleged
infringement of a Third Party’s patents or other intellectual
property right as a result of the Development or Commercialization
of the Product, the other Party shall be allowed to join in such
action, at its own expense.

 

(c) 

Status; Settlement. The Parties shall
keep each other informed of the status of and of their respective
activities regarding any litigation or settlement thereof initiated
by a Third Party concerning the Development or Commercialization of
the Product or the Licensed Technology; provided, however, that no
settlement or consent judgment or other voluntary final disposition
of a suit under this subsection ‎11.5(c) may be undertaken by
a Party without the consent of the other Party which consent shall
not be unreasonably withheld or delayed.

 

 

-22-

 

ARTICLE 12

TERM AND TERMINATION

 

12.1 

Term.

 

This
Agreement shall be effective as of the Effective Date and shall
expire on a country-by-country basis on (a) the date of expiry of
the last valid Patent in such country; or (b) the date that is
fifteen (15) years after the First Commercial Sale in such country,
whichever is last to occur, unless terminated earlier in accordance
with this Agreement (the “Term”).

 

12.2 

Termination
for Cause.

 

(a)            

Breach. This Agreement may be terminated
upon written notice by either Party if the other Party has
materially breached its obligations under this Agreement and has
not cured such breach within forty-five (45) days of receipt of
written notice of such breach by the other Party.

 

(b)            

Bankruptcy. This Agreement may be
terminated upon written notice by either Party if the other Party
(i) makes a general assignment for the benefit of creditors; (ii)
files any petition, or commences any proceeding voluntarily, for
any relief under any bankruptcy or insolvency laws or any law
relating to the relief of debtors; (iii) consents to the entry of
an order in an involuntary bankruptcy or insolvency case; (iv) is
the subject of an order or decree for relief against it by a court
of competent jurisdiction in an involuntary case under any
bankruptcy or insolvency laws or any law relating to the relief of
debtors, which order or decree is unstayed and in effect for a
period of 60 consecutive days; (v) is subject to appointment, with
or without its consent, of any receiver, liquidator, custodian,
assignee, trustee, sequestrator or other similar official of such
other Party or any substantial part of its property; or (vi) admits
in writing of its inability to pay its debts generally as they
become due.

 

(c)            

Failure to Develop or Commercialize. If
LICENSOR alleges that EDESA has failed to use commercially
reasonable efforts to Develop or Commercialize the Product,
LICENSOR shall notify EDESA of its intention to terminate this
Agreement. EDESA shall have three hundred and sixty days (360) from
receipt of notification from LICENSOR to demonstrate and satisfy
LICENSOR that commercially reasonable efforts are being used by
EDESA to Develop and Commercialize the Product, and if EDESA fails
to demonstrate and satisfy LICENSOR that commercially reasonable
efforts are being used by EDESA to Develop and Commercialize the
Product, then LICENSOR may terminate this Agreement.

 

12.3            

Termination
Without Cause.

 

EDESA
may terminate this Agreement in its entirety if it decides, in its
sole discretion, that the Development and Commercialization of the
Product is no longer commercially viable.

 

12.4 

Effect
of Termination.

 

(a) 

Upon the
termination of this Agreement, then:

 

 

-23-

 

(i) 

The license granted
to EDESA under Section ‎7.1 and any sublicenses that have
been granted to a Sublicensee with respect to Licensed Technology
shall terminate.

 

(ii) 

Unless the Parties
agree otherwise, all activities underway at the time of termination
shall be terminated as soon as possible except for winding down
activities (including such activities in connection with any
Clinical Trials) (the cost of which shall continue to be borne by
EDESA as provided in this Agreement until completion of such
activities in the normal course). For the sake of clarity, the
costs of winding down activities shall include any incurred costs
or otherwise unavoidable wind down costs that would otherwise have
been payable by EDESA.

 

(iii) 

Unless this
Agreement is terminated by EDESA pursuant to Section 12.2(a) or
12.2(b), EDESA shall transfer and
assign to LICENSOR, upon LICENSOR’s request,
all of the EDESA Data
and any patent applications and
issued patents relating to the Product owned by EDESA (the
“EDESA Assigned
IP”), provided that
LICENSOR pays all reasonable, out-of-pocket expenses actually
incurred by EDESA in connection with such transfer and assignment.
EDESA shall fully cooperate with the LICENSOR to effect such
transfer and assignment and shall execute any document and perform
any acts required to do so. The EDESA DATA SHALL BE PROVIDED
ON AN "AS IS, WHERE IS" BASIS WITHOUT ANY EXPRESS OR IMPLIED
WARRANTIES AS TO THE FITNESS FOR A PARTICULAR PURPOSE,
MERCHANTABILITY OR CONDITION OR AS TO THE NON-INFRINGEMENT OF ANY
INTELLECTUAL PROPERTY RIGHTS OF ANY PERSON OR AS TO ANY OTHER
MATTER.

 

(iv) 

For the avoidance
of doubt, the Parties acknowledge and agree that neither the
termination of this Agreement for any reason nor the assignment
contemplated by Section 12.4(a)(iii) will derogate from the force
and effect of, or otherwise limit EDESA rights under, the Exclusive
License Agreement entered into by EDESA and Yissum Research
Development Company of the Hebrew University of Jerusalem dated
June 29, 2016, as amended by the First Amendment to the Exclusive
License Agreement dated April 3, 2017 and the Second Amendment to
the Exclusive License Agreement dated May 7, 2017.

 

(v) 

Without derogating from the force and effect of
the foregoing assignment undertaking in Section 12.4(a)(iii), the
Parties acknowledge and agree that if under applicable law the
aforesaid assignment undertaking will not be fully enforceable,
then the part (if any) of such undertaking which is enforceable
shall remain in full force and effect, and the part (or whole)
which is not enforceable shall be automatically replaced with an
irrevocable grant by EDESA to LICENSOR, binding upon all of
EDESA’S acquirers, successors and assignees, of an
unrestricted, perpetual, irrevocable, world-wide, royalty-free,
exclusive license to use, exploit, transfer and sub-license (on a
multi-tier basis) the EDESA Assigned IP for any and all purposes
and uses. To the extent
permitted by applicable law, such license will be exclusive.
Notwithstanding anything to the contrary in Section 8 or elsewhere
in this Agreement, LICENSOR (on its own or via third parties) shall
be entitled to freely exploit the EDESA Assigned IP without any
obligation of confidentiality to EDESA.

 

 

-24-

 

(vi) 

Notwithstanding
anything to the contrary in this Section ‎12.4, if this
Agreement is terminated by EDESA pursuant to Section ‎12.2 or
‎12.3, EDESA shall have the right to sell its remaining
inventory of Product(s) so long as EDESA has fully paid, and
continues to pay fully when due, any and all Royalties and
Sublicensee Fees owed to LICENSOR hereunder based on such
sales.

 

(vii) 

Following any
termination of this Agreement by LICENSOR, LICENSOR shall pay to
EDESA [__] percent ([__]%) of the amounts received by LICENSOR or
its Affiliates as royalties or sublicensing fees arising from the
license of the EDESA Assigned
IP to a Third Party, up to a maximum amount equal to twice
the documented amount EDESA has expended on the Development or
Commercialization of the Product in order to generate the EDESA
Assigned IP as certified by external independent auditors agreed
upon by the Parties, less any amounts received or receivable by
EDESA from Third Parties in connection with the Licensed Technology
or the EDESA Assigned IP prior to the transfer of the EDESA
Assigned IP to EDESA. In furtherance of EDESA’s right under
this Section ‎12.4(vi), LICENSOR shall provide prompt notice
to EDESA upon the Commercialization of any products incorporating
the EDESA Assigned IP by LICENSOR or its Affiliate and upon
execution of any such license and shall thereafter provide to EDESA
written reports for each Calendar quarter and each Calendar Year;
each such report showing in relation to the reporting period, as
applicable: the net sales of any products incorporating the EDESA
Assigned IP and any the royalties and sublicensing fees received by
LICENSOR under such license. Reports in respect of a Calendar
Quarter shall be due on the thirtieth (30th) day following the
close of such Calendar Quarter and annual reports shall be due on
the sixtieth (60th) day following the close of such Calendar Year.
Royalties and sublicensing fees shown to have been received in each
report shall be due and payable by LICENSOR on the date such report
is due. LICENSOR shall keep complete and accurate records in
sufficient detail to enable the revenue sharing payments payable by
LICENSOR and its Affiliates and the royalties and sublicensing fees
received by LICENSOR under such license to be determined and EDESA
shall have the right to audit such records on terms consistent with
those set forth in Section ‎6.4 of this Agreement. For
purposes of this Section ‎12.4‎(vii): (x) the term
“net sales” shall have the same meaning as set forth on
this Agreement, but replacing references to “EDESA”
with “LICENSOR” and “Product” with
“products incorporating the EDESA Assigned IP”; (y) the
term “sublicensing fees” in relation to amounts
received from Third Parties shall have the same meanings as are set
forth in this Agreement, but replacing references to
“EDESA” with “LICENSOR” and
“Product” with “products incorporating the EDESA
Assigned IP”. [Percentage
omitted as competitively sensitive
information.]

 

 

-25-

 

12.5 

Survival.

 

Any
payments accruing hereunder shall continue to be due and owing
following termination of this Agreement. In addition, the following
provisions shall survive the termination of this Agreement for any
reason: Articles ‎1, ‎6.4, ‎8, ‎9,
‎10, ‎11.1, ‎12.4 and ‎13.

 

 

ARTICLE 13

MISCELLANEOUS

 

13.1 

Force
Majeure.

 

Neither
Party shall be held liable to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in
performing any obligation under this Agreement to the extent such
failure or delay is caused by or results from causes beyond the
reasonable control of the affected Party including embargoes, war,
acts of war (whether war be declared or not), insurrections, riots,
civil commotions, strikes, lockouts or other labour disturbances,
fire, floods, or other acts of God, or acts, pandemics, epidemics
or other viral outbreaks, governmental decisions, requests,
restrictions (including restrictions on travel and movement of
goods), or omissions or delays in acting by any governmental
authority or the other Party. The affected Party shall notify the
other Party of such force majeure circumstances as soon as
reasonably practical, and shall promptly undertake reasonable
efforts necessary to mitigate such force majeure
circumstances.

 

13.2 

Assignment.

 

No
Party may assign its rights or obligations under this Agreement
without prior written consent of the other Party, which consent
shall not be unreasonably denied, conditioned or delayed, except:
(i) as part of a sale of all or substantially all of its assets to
a Third Party, provided that such Third Party agrees, in writing,
to assume the assigning Party's obligations under this Agreement,
(ii) by LICENSOR to a successor in interest in connection with
Section 13.3 below, and (iii) that EDESA shall be entitled to
assign its rights and obligations under this Agreement to a wholly
owned subsidiary of EDESA (the “Subsidiary”) without requiring to
obtain the prior written consent of LICENSOR, provided, however, that in the event of such
assignment (a) the Subsidiary shall undertake in writing to be
bound by all the terms and conditions of this Agreement, and (b)
any such assignment shall not derogate from EDESA’s
obligations which have accrued prior to the date of such
assignment; provided, that,
in the event of any assignment by EDESA, LICENSOR shall not, as a
result of such assignment, be subject to any additional financial
or legal obligation that would not have applied to LICENSOR but for
such assignment, including without limitation, any additional tax,
impost, fee or deduction on payments (except for taxes withheld in
accordance with Section 6.6 above) made to LICENSOR pursuant to
this Agreement.

 

13.3 

Successors
and Assigns.

 

Except
as otherwise expressly stated to the contrary herein, the
provisions hereof shall inure to the benefit of, and be binding
upon, heirs, executors, and administrators of the parties hereto
and their respective successors and assigns.

 

 

-26-

 

13.4 

Severability.

 

If any
one or more of the provisions contained in this Agreement is held
invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained
herein shall not in any way be affected or impaired thereby, unless
the absence of the invalidated provision(s) adversely affects the
substantive rights of the Parties. The Parties shall in such an
instance use their commercially reasonable efforts to replace the
invalid, illegal or unenforceable provision(s) with valid, legal
and enforceable provision(s) which, insofar as practical, implement
the purposes of this Agreement.

 

13.5 

Notices.

 

All
notices which are required or permitted hereunder shall be in
writing and sufficient if delivered personally, sent by email (and
promptly confirmed by personal delivery, registered or certified
mail or overnight courier), sent by nationally-recognized overnight
courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows:

 

	

if to
LICENSOR, to:

 

	

Dr.
Saul Yedgar

[_______]

Email:

 

	

with a
copy (which shall not constitute notice) to:

	

Attn:
Adv. Yuval Horn

Email:

	

if to
EDESA, to:

	

Edesa
Biotech Inc.

Attn:
President

100 Spy
Court

Markham,
Ontario

L3R
5H6

Email:

 

	

with a
copy (which shall not constitute notice) to:

	

Attn:
Wojtek Baraniak

Email:

 

or to
such other address as the Party to whom notice is to be given may
have furnished to the other Party in writing in accordance
herewith. Any such notice shall be deemed to have been given: (a)
when delivered if personally delivered or sent by email on a
business day; (b) on the business day after dispatch if sent by
nationally-recognized overnight courier; or (c) on the fifth
business day following the date of mailing if sent by mail.
[Personal information
omitted.]

 

 

-27-

 

13.6 

Applicable
Law and Litigation.

 

This
Agreement shall be governed by and construed in accordance with the
laws of the England and Wales, without reference to any rules of
conflict of laws, except that questions affecting the construction
and effect of any patent shall be determined by the law of the
country in which the patent shall have been granted (other than for
matters of inventorship on patents). For controversies, claims and
disputes not covered by the arbitration provisions pursuant to
Section ‎13.15, and for injunctive or other equitable interim
relief in relation to all controversies, claims and disputes
arising out of or relating to this Agreement, the Parties
irrevocably and unconditionally: (a) consent to the exclusive
jurisdiction of the courts of England, located in London for any
action, suit or proceeding, and agree not to commence any action,
suit or proceeding related thereto except in such courts; and (b)
waive any objection to the laying of venue of any action, suit or
proceeding in the courts of England, located in London and waive
and agree not to plead or claim in any such court that any such
action, suit or proceeding brought in any such court has been
brought in an inconvenient forum.

 

13.7 

Entire
Agreement; Amendments.

 

This
Agreement contains the entire understanding of the Parties with
respect to the subject matter hereof. All express or implied
agreements and understandings, either oral or written, with regard
to the subject matter hereof are superseded by the terms of this
Agreement. This Agreement may be amended, or any term hereof
modified, only by a written instrument duly executed by authorized
representatives of both Parties.

 

13.8 

Independent
Contractors.

 

The
Parties shall be independent contractors and the relationship
between the Parties shall not constitute a partnership, joint
venture or agency. Neither Party shall have the authority to make
any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without
the prior written consent of the other Party.

 

13.9 

Waiver.

 

The
waiver by either Party of any right hereunder, or the failure of
the other Party to perform, or a breach by the other Party, shall
not be deemed a waiver of any other right hereunder or of any other
breach or failure by such other Party whether of a similar nature
or otherwise.

 

13.10 

Cumulative
Remedies.

 

No
remedy referred to in this Agreement is intended to be exclusive,
but each shall be cumulative and in addition to any other remedy
referred to in this Agreement or otherwise available under
law.

 

13.11 

Waiver
of Rule of Construction.

 

Each
Party has had the opportunity to consult with legal counsel in
connection with the review, drafting and negotiation of this
Agreement. Accordingly, the rule of construction that any ambiguity
in this Agreement shall be construed against the drafting Party
shall not apply.

 

 

-28-

 

13.12 

Further
Assurances.

 

Each
Party shall duly execute and deliver, or cause to be duly executed
and delivered, such further instruments and do and cause to be done
such further acts and things, including the filing of such
assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the
provisions and purposes, or to better assure and confirm unto such
other Party its rights and remedies under this Agreement. Each
Party shall use its commercially reasonable efforts to take all
actions necessary or advisable under applicable laws to consummate
and make effective the transactions contemplated by this Agreement
including the taking of such reasonable actions as are necessary to
obtain any requisite approvals, consents, orders, exemptions or
waivers by any governmental authority.

 

13.13 

Construction.

 

Except
where the context otherwise requires, wherever used, the singular
will include the plural, the plural the singular, the use of any
gender will be applicable to all genders, and the word
“or” is used in the inclusive sense (and/or). The
captions of this Agreement are for convenience of reference only
and in no way define, describe, extend or limit the scope or intent
of this Agreement or the intent of any provision contained in this
Agreement. The term “including” as used herein means
including, without limiting the generality of any description
preceding such term. References to “Section” or
“Sections” are references to the numbered sections of
this Agreement, unless expressly stated otherwise.

 

13.14 

Currency.

 

All
payments under this Agreement shall be made in United States
Dollars. All references to “dollars” or “$”
in this Agreement are to United States Dollars.

 

13.15 

Dispute
Resolution.

 

(a) 

Any controversy,
claim or dispute arising out of or relating to this Agreement shall
first be submitted to the CEO of each Party for attempted
resolution. If the CEOs of the Parties do not resolve such matter
within thirty (30) days of the matter being submitted to them, then
such matter shall be resolved through binding arbitration as
follows. For the sake of clarity, this Section ‎13.15 is not
intended to alter the rights of the Parties as established by
Section ‎13.6, herein. The dispute shall be resolved by final
and binding arbitration. The place of arbitration shall be London,
England. The arbitration shall be in accordance with the rules of
LCIA except as modified
herein. The number of arbitrators shall be three. The language of
the arbitration shall be English.

 

(b) 

The Party wishing
to commence an arbitration (“Claimant”) shall notify the other
party (“Respondent”) in writing of its
decision to commence arbitration hereunder (sometimes referred to
in this Agreement as its “demand for arbitration”), setting
out briefly its claims in its notice, and with its notice, name the
arbitrator it is appointing.

 

 

-29-

 

(c) 

The Respondent
shall, within thirty (30) days of receipt of a demand for
arbitration, notify the Claimant in writing of the name of the
arbitrator it is appointing.

 

(d) 

The third
arbitrator shall be chosen by the first two arbitrators within
twenty (20) days after the second of such arbitrators was
appointed.

 

(e) 

All arbitrators
shall be chosen taking into account the type of issues to be
addressed in the arbitration, whether legal, business, scientific,
or a combination thereof, and having regard to their availability
to conduct the arbitration within the times provided
below.

 

(f) 

Within thirty (30)
days of completion of the hearing, the arbitrators shall render a
reasoned arbitration award describing, in writing, the essential
finding and conclusions on which the decision is based, including
the calculation of any damages awarded. Any monetary award shall be
made within thirty (30) days of the rendering of such
award.

 

(g) 

All information and
documents in relation to the arbitration shall be deemed
Confidential Information to the full extent permitted by law. No
individual shall be appointed as an arbitrator unless the
individual first agrees in writing to be bound by this subsection
and to conduct the arbitration in a manner that in his/her judgment
is most likely to maintain the confidentiality of Confidential
Information. Neither Party may retain any expert in connection with
the arbitration unless the expert first agrees in writing to be
bound by this subsection, as applicable. The fact of and subject
matter of the arbitration, including the fact that any dispute has
been submitted to arbitration, and all evidence given and
submissions made in connection with any arbitration, shall be
Confidential Information, and shall be treated as such by the
Parties and all persons employed by or contracted to them. Any
meetings, conferences or hearings in connection with or during the
arbitration may be attended only by those individual persons whose
presence, in the opinion of the arbitral tribunal, is reasonably
necessary for the determination or other resolution of the dispute
and such person first agrees in writing to be bound by the
provisions of these sections, as applicable. The obligations under
this subsection continue notwithstanding any determination or other
resolution of the arbitration.

 

(h) 

The arbitrators
shall be paid reasonable fees plus expenses. These fees and
expenses, along with the reasonable legal fees and expenses of the
prevailing Party (including all expert witness fees and expenses),
the fees and expenses of a court reporter, and any expenses for a
hearing room, shall be paid as follows:

 

(i) 

If the arbitrators
rule in favour of one Party on all disputed issues in the
arbitration, the losing Party shall pay 100% of such fees and
expenses.

 

(ii) 

If the arbitrators
rule in favour of one Party on some issues and the other Party on
other issues, the arbitrators shall issue with the ruling a written
determination as to how such fees and expenses shall be allocated
between the Parties. The arbitrators shall allocate fees and
expenses in a way that bears a reasonable relationship to the
outcome of the arbitration, with the Party prevailing on more
issues, or on issues of greater value or gravity, recovering a
relatively larger share of its legal fees and
expenses.

 

 

-30-

 

(i) 

Any final award of
the arbitrators shall be final, conclusive and binding on the
Parties, and judgment may be entered in any court of competent
jurisdiction. To the extent lawful, the Parties exclude any right
of review or appeal to Canadian, United States, English, Israeli or
other courts, including in connection with any question of law
arising in the arbitration or in connection with any award or
decision made by the arbitrators, except as is necessary to
recognize or enforce such award or decision.

 

13.16 

Statute
of Limitations.

 

In no
event will a demand for arbitration be made after the date when
institution of a legal or equitable proceeding based upon such a
dispute between the Parties would otherwise be barred by the
applicable statute of limitations.

 

13.17 

Injunctive
and Other Interim Relief.

 

Nothing
in this Agreement shall be construed as limiting in any way the
right of a Party to seek injunctive or other interim relief from a
court of competent jurisdiction with respect to any actual or
threatened breach of this Agreement, or to preserve or protect any
property or assets pending an arbitral award, or otherwise in
support of the contemplated or pending arbitration. No such court
application shall be taken as a waiver or impairment of
arbitration.

 

 

 

13.18 

Execution
in Counterparts; Facsimile Signatures.

 

This
Agreement may be executed in counterparts, each of which
counterpart, when so executed and delivered, shall be deemed to be
an original, and all of which counterparts, taken together, shall
constitute one and the same instrument even if both Parties have
not executed the same counterpart. Signatures provided by facsimile
transmission or scanned and emailed copies shall be deemed to be
original signatures.

 

 [Remainder
of the Page Intentionally Left Blank]

 

 

-31-

 

 

The
Parties have executed this Agreement as of the Effective
Date.

 

	
 

	
 

	

SAUL YEDGAR

 

	
 

	
 

	
 

	

By:

	

s/ Saul
Yedgar

	
 

	
 

	
 

	
 

	

Name: Saul
Yedgar

Title: Licensor

	
 

	
 

	
 

	

By:

	
 

	
 

	
 

	
 

	
 

	

Name:

Title:

 

 

 

 

	
 

	
 

	

EDESA BIOTECH RESEARCH INC.

 

	
 

	
 

	
 

	

By:

	

/s/
Pardeep Njihawan

	
 

	
 

	
 

	
 

	

Name: Dr.
Pardeep Nijhawan

Title: Chief
Executive Officer

	
 

	
 

	
 

	

By:

	
 

	
 

	
 

	
 

	
 

	

Name:

Title:

 

 

 

 

 

-32-

 

Appendix
A

 

(Patents)

 

[______________]

 

[List of Patents, including countries, owners, patent or application
numbers, status and expiration dates, omitted as competitively
sensitive information.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]